

Edgar Filing: CYTEC INDUSTRIES INC/DE/ - Form 10-Q

CYTEC INDUSTRIES INC/DE/
Form 10-Q
October 30, 2008

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2008

Commission file number 1-12372

CYTEC INDUSTRIES INC.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation or organization)

22-3268660
(I.R.S. Employer
Identification No).

Five Garret Mountain Plaza
West Paterson, New Jersey
(Address of principal executive offices)

07424
(Zip Code)

Registrant's telephone number, including area code (973) 357-3100

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes No .

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a small reporting company. See definition of "accelerated filer, large accelerated filer, and smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer Accelerated filer Non-accelerated filer
Small reporting company

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

There were 47,113,947 shares of common stock outstanding at October 23, 2008.

-1-

CYTEC INDUSTRIES INC. AND SUBSIDIARIES
10-Q Table of Contents

Edgar Filing: CYTEC INDUSTRIES INC/DE/ - Form 10-Q

Part I - Financial Information		Pa
Item 1. Consolidated Financial Statements		3
Consolidated Statements of Income		3
Consolidated Balance Sheets		4
Consolidated Statements of Cash Flows		5
Notes to Consolidated Financial Statements		6
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations		2
Item 3. Quantitative and Qualitative Disclosures About Market Risk		3
Item 4. Controls and Procedures		3
Part II - Other Information		
Item 1. Legal Proceedings		3
Item 1A. Risk Factors		3
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds		3
Item 6. Exhibits		3
Signature		3
Exhibit Index		3

-2-

PART I - FINANCIAL INFORMATION

Item 1. CONSOLIDATED FINANCIAL STATEMENTS

CYTEC INDUSTRIES INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME
(Unaudited)
(Dollars in millions, except per share amounts)

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2008	2007	2008	2007
Net sales	\$ 963.0	\$ 875.1	\$ 2,941.7	\$ 2,602.6
Manufacturing cost of sales	765.8	683.8	2,334.6	2,045.6
Selling and technical services	57.4	52.3	176.1	155.3
Research and process development	19.2	18.0	62.5	55.5
Administrative and general	30.8	29.2	89.6	84.4
Amortization of acquisition intangibles	10.0	9.7	30.4	28.6
Gain on sale of assets held for sale	-	-	-	15.7
	-----	-----	-----	-----
Earnings from operations	79.8	82.1	248.5	248.9
Other (expense) income, net	(2.1)	(1.4)	1.0	0.1
Equity in earnings of associated companies	0.4	0.5	1.4	0.9
Interest expense, net	8.7	10.4	27.8	31.9
	-----	-----	-----	-----
Earnings before income taxes	69.4	70.8	223.1	218.0
Income tax provision	23.1	18.4	71.1	59.1
	-----	-----	-----	-----
Net earnings	\$ 46.3	\$ 52.4	\$ 152.0	\$ 158.9
	=====	=====	=====	=====

Edgar Filing: CYTEC INDUSTRIES INC/DE/ - Form 10-Q

Basic net earnings per common share	\$	0.97	\$	1.09	\$	3.17	\$	3.30
Diluted net earnings per common share	\$	0.96	\$	1.06	\$	3.12	\$	3.23
Dividends per common share	\$	0.125	\$	0.10	\$	0.375	\$	0.30
		=====		=====		=====		=====

See accompanying Notes to Consolidated Financial Statements

-3-

CYTEC INDUSTRIES INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(Unaudited)
(Dollars in millions, except per share amounts)

	September 30, 2008	December 2007
<hr/>		
Assets		
Current assets		
Cash and cash equivalents	\$ 90.2	\$
Trade accounts receivable, less allowance for doubtful accounts of \$3.9 and \$4.5 at September 30, 2008 and December 31, 2007, respectively	619.7	
Other accounts receivable	72.7	
Inventories	609.8	
Deferred income taxes	8.9	
Other current assets	23.6	
<hr/>		
Total current assets	1,424.9	
<hr/>		
Investment in associated companies	22.6	
Plants, equipment and facilities	2,102.9	
Less: accumulated depreciation	(1,024.9)	
<hr/>		
Net plant investment	1,078.0	
<hr/>		
Acquisition intangibles, net of accumulated amortization of \$166.4 and \$139.3 at September 30, 2008 and December 31, 2007, respectively	449.3	
Goodwill	1,091.9	
Deferred income taxes	0.5	
Other assets	126.3	
<hr/>		
Total assets	\$ 4,193.5	\$
<hr/>		
Liabilities		
Current liabilities		
Accounts payable	\$ 363.8	\$
Short-term borrowings	39.8	
Current maturities of long-term debt	1.5	
Accrued expenses	216.5	
Income taxes payable	15.6	
Deferred income taxes	14.4	
<hr/>		
Total current liabilities	651.6	

Edgar Filing: CYTEC INDUSTRIES INC/DE/ - Form 10-Q

Long-term debt	823.5
Pension and other postretirement benefit liabilities	266.9
Other noncurrent liabilities	334.4
Deferred income taxes	139.0
Stockholders' equity	
Common stock, \$.01 par value per share, 150,000,000 shares authorized; issued 48,132,640 shares	0.5
Additional paid-in capital	433.8
Retained earnings	1,490.5
Accumulated other comprehensive income	111.8
Treasury stock, at cost, 1,094,050 shares in 2008 and 596,911 shares in 2007	(58.5)
Total stockholders' equity	1,978.1
Total liabilities and stockholders' equity	\$ 4,193.5

See accompanying Notes to Consolidated Financial Statements

-4-

CYTEC INDUSTRIES INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(Dollars in millions)

	Nine Months Ended September 30,	
	2008	2007
Cash flows provided by (used in) operating activities		
Net earnings	\$ 152.0	\$
Noncash items included in net earnings:		
Depreciation	84.8	
Amortization	35.1	
Share-based compensation	8.5	
Deferred income taxes	11.9	
Gain on sale of assets held for sale	-	
Other	1.0	
Changes in operating assets and liabilities:		
Trade accounts receivable	(48.7)	
Other receivables	(0.3)	
Inventories	(97.1)	
Other assets	(10.8)	
Accounts payable	39.3	
Accrued expenses	4.9	
Income taxes payable	12.1	
Other liabilities	(22.2)	
Net cash provided by operating activities	170.5	
Cash flows (used in) provided by investing activities		
Additions to plants, equipment and facilities	(116.3)	
Net proceeds (paid)/received on sale of assets	(4.7)	

Edgar Filing: CYTEC INDUSTRIES INC/DE/ - Form 10-Q

Net cash used in investing activities	(121.0)		
Cash flows provided by (used in) financing activities			
Proceeds from long-term debt	241.0		
Payments on long-term debt	(222.6)		
Change in short-term borrowings, net	(2.9)		
Cash dividends	(17.9)		
Proceeds from the exercise of stock options	10.8		
Purchase of treasury stock	(46.4)		
Excess tax benefits from share-based payment arrangements	2.7		
Other	0.6		
Net cash used in financing activities	(34.7)		
Effect of currency rate changes on cash and cash equivalents	(1.4)		
Increase in cash and cash equivalents	13.4		
Cash and cash equivalents, beginning of period	76.8		
Cash and cash equivalents, end of period	\$ 90.2	\$	

See accompanying Notes to Consolidated Financial Statements

-5-

CYTEC INDUSTRIES INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

(Currencies in millions, except per share amounts, unless otherwise indicated)

1. BASIS OF PRESENTATION

The accompanying unaudited consolidated financial statements included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission for reporting on Form 10-Q and accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim reporting. Certain information and footnote disclosures normally included in our annual financial statements have been condensed or omitted pursuant to such rules and regulations. Financial statements prepared in accordance with U.S. GAAP require management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses and other disclosures. In the opinion of management, these financial statements include all normal and recurring adjustments necessary for a fair presentation of the financial position and the results of our operations and cash flows for the interim periods presented. As discussed in our June 30, 2008 Form 10-Q, the tax benefit/(cost) related to unrealized gains/(losses) on our cross currency swaps included in accumulated other comprehensive income and deferred tax liabilities has been revised for all prior periods presented. See Note 10 of these Consolidated Financial Statements for additional details on the revision. The results of operations for any interim period are not necessarily indicative of the results of operations for the full year. The financial statements should be read in conjunction with the Consolidated Financial Statements and Notes to the Consolidated Financial Statements contained in the Company's 2007 Annual Report on Form 10-K. Unless indicated otherwise, the terms "Company", "Cytec", "we", "us" and "our" each refer collectively to Cytec Industries Inc. and its subsidiaries.

2. NEWLY ISSUED ACCOUNTING PRONOUNCEMENTS

In June 2008, the Financial Accounting Standards Board ("FASB") issued FASB

Edgar Filing: CYTEC INDUSTRIES INC/DE/ - Form 10-Q

Staff Position ("FSP") EITF No. 03-6-1, "Determining Whether Instruments Granted in Share-Based Payment Transactions Are Participating Securities". The FSP addresses whether instruments granted in share-based payment transactions are participating securities prior to vesting and therefore need to be included in the earnings allocation in calculating earnings per share under the two-class method described in Statement of Financial Accounting Standards ("SFAS") SFAS No. 128, "Earnings per Share." The FSP requires entities to treat unvested share-based payment awards that have non-forfeitable rights to dividend or dividend equivalents as a separate class of securities in calculating earnings per share. The FSP is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2008 and earlier application is not permitted. We expect the effect of the adoption of FSP EITF No. 03-6-1 to be immaterial to our consolidated financial statements and earnings per share.

In March 2008, the FASB issued SFAS No. 161, "Disclosures about Derivative Instruments and Hedging Activities - an amendment of FASB Statement No. 133," ("SFAS 161"), which requires enhanced disclosures about an entity's derivative and hedging activities. In addition to disclosing the fair values of derivative instruments and their gains and losses in a tabular format, entities are required to provide enhanced disclosures about (a) how and why an entity uses derivative instruments, (b) how derivative instruments and related hedged items are accounted for under Statement 133 and its related interpretations, and (c) how derivative instruments and related hedged items affect an entity's financial position, financial performance, and cash flows. SFAS 161 is effective for financial statements issued for fiscal years, and interim periods within those fiscal years, beginning after November 15, 2008. SFAS 161 does not change the accounting for derivative instruments.

In December 2007, the FASB issued SFAS No. 141R, "Business Combinations", ("SFAS 141R"), which establishes principles and requirements for how an acquirer recognizes and measures in its financial statements the identifiable assets acquired, the liabilities assumed, any noncontrolling interest in an acquiree, and the recognition and measurement of goodwill acquired in a business combination or a gain from a bargain purchase. SFAS 141R applies prospectively to business combinations for which the acquisition date is on or after the beginning of the first annual reporting period beginning on or after December 15, 2008.

In December 2007, the FASB issued SFAS No. 160, "Noncontrolling Interest in Consolidated Financial Statements, an amendment of ARB No. 51", ("SFAS 160"), which establishes accounting and reporting standards that require the noncontrolling interest to be identified, labeled, and presented in the consolidated statement of financial position within equity, but separate from the parent's equity. SFAS 160 will also require that the amount of consolidated net income attributable to the parent and to the noncontrolling interest be identified and presented on the face of the consolidated statement of income. SFAS 160 is effective for fiscal years, and interim periods within those fiscal years, beginning on or after December 15, 2008. We do not expect the adoption of SFAS 160 to have a material impact on our consolidated financial statements.

-6-

In September 2006, the FASB issued SFAS No. 157, "Fair Value Measurements", ("SFAS 157"). SFAS 157 establishes a single authoritative definition of fair value, sets out a framework for measuring fair value, and requires additional disclosures about fair value measurements. SFAS 157 applies only to fair value measurements that are already required or permitted by other accounting standards (except for measurements of share-based payments) and is intended to increase the consistency of those measurements. Accordingly, SFAS 157 does not require any new fair value measurements. On January 1, 2008, we adopted SFAS 157 for financial assets and liabilities, as well as for any other assets and

Edgar Filing: CYTEC INDUSTRIES INC/DE/ - Form 10-Q

liabilities that are carried at fair value on a recurring basis in financial statements. As of September 30, 2008, we did not have any non-financial assets and liabilities that are carried at fair value on a recurring basis. The FASB has issued a one-year deferral of SFAS 157's fair value measurement requirements for non-financial assets and liabilities that are not required or permitted to be measured at fair value on a recurring basis. Included among our non-financial assets and liabilities that are not required to be measured at fair value on a recurring basis are long-lived assets, goodwill, acquisition intangibles, and asset retirement obligations for which we will provide the required disclosures upon adoption of the remainder of SFAS 157 effective January 1, 2009. See Note 15 of the Consolidated Financial Statements for additional details on the impact of adoption of SFAS 157.

3. DIVESTITURES

In October 2006, we completed the first of three phases of the sale of our water treatment chemicals and acrylamide product lines to Kemira Group ("Kemira"). This first phase included the product lines themselves, the related intellectual property, the majority of the manufacturing sites and essentially all of the sales, marketing, manufacturing, research and development and technical services personnel. The manufacturing sites in the first phase included Mobile, Alabama, Longview, Washington, Bradford, UK, and the acrylamide manufacturing plant at our Fortier, Louisiana facility, which continues to be operated by our personnel under a long-term manufacturing agreement. The sale of our Botlek manufacturing site in the Netherlands was completed and transferred to Kemira in January 2007 as part of the phase two closing. We continue to supply acrylonitrile to the Kemira acrylamide plants at Fortier and Botlek under long-term supply agreements. In addition, under various long-term manufacturing agreements, we manufacture certain water treatment products for Kemira at several of our sites and Kemira manufactures certain mining chemicals for us at the Mobile, Alabama and Longview, Washington sites and various other products at the Botlek site. These contracts were all deemed to be at estimated market value. Sales of certain assets at subsidiaries in Asia/Pacific and Latin America were settled in the third and fourth quarters of 2007 and the transfer of our subsidiary in Venezuela was completed in the fourth quarter of 2007 as the last phase of the transaction.

The timing of the flow of funds was as follows: \$208.0 (\$206.6 net of associated transaction costs) was received in October 2006 for the first closing, and \$21.2 was received for the second closing in January 2007. We also received \$5.9 in February 2007 for a working capital adjustment from the first phase closing per the terms of the contract. During the third quarter of 2007, we received \$3.1 from completed transfers of the assets at various subsidiaries in Asia/Pacific and Latin America, and \$8.5 was received in the fourth quarter of 2007 in settlement of the final working capital transfers in Asia/Pacific and Latin America and for the sale of our subsidiary in Venezuela.

At the time of the sale of the manufacturing facilities included in this transaction, Kemira agreed to assume certain environmental liabilities related to those sites and we agreed to compensate Kemira for the estimated costs of required remedial actions identified in a subsequent site evaluation or to undertake such actions on behalf of Kemira. Negotiations with Kemira over the required remedial actions and their estimated costs were completed in the first quarter of 2008. As a result of these negotiations, in the first quarter of 2008 we paid Kemira approximately \$1.9 in exchange for their agreement to assume the environmental liabilities related to one of the transferred sites. A final payment to Kemira for \$2.8 was made in the second quarter of 2008 in accordance with their agreement to assume environmental liabilities related to the last of the transferred sites (see Note 9 of the Consolidated Financial Statements). After adjusting for these environmental settlements, final net proceeds related to this transaction were \$242.0 (\$240.6 net of associated transaction costs).

Edgar Filing: CYTEC INDUSTRIES INC/DE/ - Form 10-Q

We recorded a pre-tax gain of \$75.5 (\$59.6 after-tax) related to the first phase closing in the fourth quarter of 2006, and a pre-tax gain of \$13.6 (\$13.3 after-tax) in 2007 from other closings and other activities. The 2007 gain consists of a pre-tax gain of \$15.7 (\$15.3 after-tax) recorded in the first quarter related to the phase two sale of the Botlek site, which includes a pre-tax gain of \$13.8 resulting from the recognition of accumulated translation adjustments, and a pre-tax loss of \$2.1 (\$2.0 after-tax) recorded in the fourth quarter. The fourth quarter 2007 loss included a loss on the transfer of the Venezuela subsidiary, an accrual to increase recorded environmental liabilities related to sites previously transferred to Kemira based on additional information generated by updated site evaluations, and a favorable adjustment, based on final actuarial reports, to a pension settlement loss accrued in the first quarter of 2007 related to the sale of the Botlek site.

4. RESTRUCTURING OF OPERATIONS

In accordance with our policy for segment reporting, restructuring costs are included in our corporate and unallocated operating results consistent with management's view of its businesses.

For the three and nine months ended September 30, 2008, we recorded net restructuring charges of \$5.7 and \$10.8, respectively, primarily related to the 2008 and 2007 restructuring initiatives as described below.

-7-

During the third quarter of 2008, as a cost savings and reduction initiative and to re-align our staff levels with our latest view of the global economy, we decided to restructure several areas primarily in our Surface Specialties segment, resulting in the elimination of 39 positions. The restructuring charge of \$5.4 for the three and nine months ended September 30, 2008 primarily relates to severance and was charged to expense as follows: manufacturing cost of sales of \$1.3, selling and technical services of \$2.7, administrative and general of \$1.3, and research and process development of \$0.1.

During the first quarter of 2008, we decided to restructure several areas primarily in our Surface Specialties segment, resulting in the elimination of 13 positions. The restructuring charge of \$1.6 for the nine months ended September 30, 2008 primarily relates to severance and was charged to expense as follows: selling and technical services of \$0.8, administrative and general of \$0.3, and research and process development of \$0.5.

Details of 2007 restructuring initiatives are as follows:

We decided to cease manufacturing of several mature products at our Willow Island, West Virginia plant. The discontinued products were part of the polymer additives product line in our Cytec Performance Chemicals segment. As a result, we recorded a restructuring charge of \$2.6 to 2007 manufacturing cost of sales primarily related to severance and other benefits earned through 2007 by the 63 employees who were retained through May 2008. This charge also included the write-off of excess raw materials and spare parts. For the three and nine months ended September 30, 2008, we recorded additional restructuring charges of \$0.0 and \$2.9 to manufacturing cost of sales for severance and other benefits earned. The remaining reserve relating to this restructuring initiative is expected to be paid by early 2009.

We also announced the restructuring of our liquid coating resins plant in Wallingford, Connecticut in order to exit a mature product line and consolidate and automate certain operations at the site. Liquid coating resins are part of the Cytec Surface Specialties segment. We recorded a restructuring charge of \$1.4 to 2007 manufacturing cost of sales relating to severance and other benefits for 31 employees. For the three and nine months ended September 30,

Edgar Filing: CYTEC INDUSTRIES INC/DE/ - Form 10-Q

2008, we recorded additional restructuring charges of \$0.0 and \$0.3 to manufacturing cost of sales for severance and other benefits earned. A final restructuring charge of \$0.1 is expected to be recorded in the fourth quarter of 2008, primarily related to the remainder of the severance and other benefits which will be accrued as they are earned. The economic benefit of this restructuring is derived from the combination of ceasing operations of one manufacturing line and supplying the volume on a consolidated operating basis. The remaining reserve relating to this restructuring initiative is expected to be paid by early 2009.

Asset retirements resulting from the Willow Island and Wallingford projects are being recorded as they are dismantled, and are charged to the composite depreciation reserve in accordance with our accounting policy.

We also incurred additional net restructuring charges of \$0.2 and \$0.5 to manufacturing cost of sales for the three and nine months ended September 30, 2008, respectively, primarily for severance and facility closing costs relating to a restructuring initiative announced in 2006 for the shutdown of our manufacturing operation in Dijon, France. These expenses were anticipated but not accruable when the plans were announced.

A summary of the restructuring activity is outlined in the table below:

	2005 Restructuring Initiatives	2006 Restructuring Initiatives	2007 Restructuring Initiatives	R

Balance				
December 31, 2006	\$ 1.4	\$ 13.5	\$ -	\$

2007 charges	(0.2) (1)	2.4	4.0	
Non-cash items	-	(0.3) (2)	-	
Cash payments	(1.0)	(11.5)	(0.6)	
Currency translation adjustments	0.1	0.7	-	

Balance				
December 31, 2007	\$ 0.3	\$ 4.8	\$ 3.4	\$

1st Quarter charges	-	0.3 (3)	1.6	
Non-cash items	-	-	-	
Cash payments	-	(1.2)	(0.6)	
Currency translation adjustments	-	0.4	-	
Balance				
March 31, 2008	\$ 0.3	\$ 4.3	\$ 4.4	\$

2nd Quarter charges	-	- (4)	1.6	
Non-cash items	-	-	-	
Cash payments	-	(0.8)	(2.0)	
Currency translation adjustments	-	(0.2)	-	

Balance				
June 30, 2008	\$ 0.3	\$ 3.3	\$ 4.0	\$

3rd Quarter charges	-	0.3 (3)		
Non-cash items	-	-	(0.3) (5)	
Cash payments	(0.1)	(0.6)	(1.2)	
Currency translation adjustments	-	(0.2)	-	

Balance				
September 30, 2008	\$ 0.2	\$ 2.8	\$ 2.5	\$

Edgar Filing: CYTEC INDUSTRIES INC/DE/ - Form 10-Q

- (1) Represents a reduction in estimated severance and other costs.
- (2) Represents asset impairment charge at the Indian Orchard facility.
- (3) Represents a charge for severance relating to a restructuring initiative for the manufacturing operation in Dijon, France.
- (4) Includes a \$0.6 charge related to facility closing costs offset by \$0.4 benefit related to a reversal of excess severance accrual relating to the Dijon, France facility and a benefit of \$0.2 for the Corporate restructuring initiative for which all payments have been completed.
- (5) Represents a write-off of excess raw materials at the Willow Island facility.

-8-

5. SHARE-BASED COMPENSATION

For stock options granted before January 1, 2005, the fair value of each stock option grant was estimated on the date of grant using the Black-Scholes option pricing model. For stock options and stock appreciation rights that are settled with common shares ("stock-settled SARS") granted after January 1, 2005, the fair value of each award is estimated on the date of grant using a binomial-lattice option valuation model. Stock-settled SARS are economically valued the same as stock options. The binomial-lattice model considers characteristics of fair value option pricing that are not available under the Black-Scholes model. Similar to the Black-Scholes model, the binomial-lattice model takes into account variables such as volatility, dividend yield, and risk-free interest rate. However, in addition, the binomial-lattice model considers the contractual term of the option, the probability that the option will be exercised prior to the end of its contractual life, and the probability of termination or retirement of the option holder in computing the value of the option. For these reasons, we believe that the binomial-lattice model provides a fair value that is more representative of actual experience and future expected experience than the value calculated in previous years using Black-Scholes. The assumptions for the nine months ended September 30, 2008 and 2007 are noted in the following table:

	2008	2007
Expected life (years)	6.6	6.2
Expected volatility	31.0%	27.2%
Expected dividend yield	0.76%	0.69%
Range of risk-free interest rate	2.1% - 3.7%	4.8% - 5.2%
Weighted-average fair value per option	\$17.65	\$19.50

The expected life of options granted is derived from the output of the option valuation model and represents the period of time that options granted are expected to be outstanding. Expected volatilities are based on the combination of implied market volatility and our historical volatility. The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of grant. SFAS No. 123 (revised 2004), "Share-Based Payment", ("SFAS 123R") specifies that initial accruals be based on the estimated number of instruments for which the requisite service is expected to be rendered. Therefore, we are required to incorporate the probability of pre-vesting forfeiture in determining the number of expected vested options. The forfeiture rate is based on the historical forfeiture experience and prospective actuarial analysis.

-9-

A summary of stock options and stock-settled SARS activity for the nine months ended September 30, 2008 is presented below.

Edgar Filing: CYTEC INDUSTRIES INC/DE/ - Form 10-Q

Options and Stock-Settled SARS Activity:	Number of Units	Weighted Average Exercise Price Per Unit	Weighted Average Remaining Contractual Life (Years)	Aggregate Intrinsic Value
Outstanding at January 1, 2008	3,600,932	\$38.35		
Granted	556,652	52.62		
Exercised	(397,614)	30.29		
Forfeited	(68,663)	48.76		
Outstanding at September 30, 2008	3,691,307	\$41.18	5.7	\$17.8
Exercisable at September 30, 2008	2,620,958	\$35.98	4.5	\$17.8

Nonvested Options and Stock-Settled SARS:	Number of Units	Weighted Average Grant Date Fair Value
Nonvested at January 1, 2008	1,048,662	\$19.09
Granted	556,652	17.65
Vested	(494,152)	18.77
Forfeited	(40,813)	18.80
Nonvested at September 30, 2008	1,070,349	\$18.47

During the nine months ended September 30, 2008, we granted 556,652 shares of stock-settled SARS and stock options. The weighted-average grant-date fair value of the stock-settled SARS and stock options granted during the nine months ended September 30, 2008 and 2007 was \$17.65 and \$19.50 per share, respectively. Stock-settled SARS are deemed to be equity-based awards under SFAS 123R. The total intrinsic value of stock options and stock-settled SARS exercised during the nine months ended September 30, 2008 and 2007 was \$10.7 and \$24.9, respectively. Treasury shares have been utilized for stock option and stock-settled SARS exercises. The total fair value of stock options and stock-settled SARS vested during the nine months ended September 30, 2008 and 2007 was \$9.3 and \$9.1, respectively.

As of September 30, 2008, there was \$8.8 of total unrecognized compensation cost related to stock options and stock-settled SARS. That cost is expected to be recognized over a weighted-average period of 1.6 years as the majority of our awards vest over three years. Compensation cost related to stock options and stock-settled SARS capitalized in inventory as of September 30, 2008 and December 31, 2007 was approximately \$0.4 and \$0.3, respectively.

Cash received (for stock options only) and the tax benefit realized from stock options and stock-settled SARS exercised were \$10.8 and \$3.3 for the nine months ended September 30, 2008 and \$31.8 and \$9.1 for the nine months ended September 30, 2007, respectively. Cash used to settle cash-settled SARS was \$0.1 and \$0.8 for the nine months ended September 30, 2008 and 2007, respectively. The liability related to our cash-settled SARS was \$2.2 at September 30, 2008 and \$4.3 at December 31, 2007.

Edgar Filing: CYTEC INDUSTRIES INC/DE/ - Form 10-Q

As provided under the 1993 Plan, we have also issued non-vested stock and performance stock. Non-vested shares are subject to certain restrictions on ownership and transferability that lapse upon vesting. Performance share payouts are based on the attainment of certain financial performance objectives and may vary depending on the degree to which the performance objectives are met. During the nine months ended September 30, 2008, we granted performance stock awards for 47,927 shares (assuming par payout) to nine employees, which relate to the 2010 performance period. The total amount of share-based compensation expense recognized for non-vested and performance stock for three months ended September 30, 2008 and 2007 was \$0.3 and \$0.1, respectively, and for nine months ended September 30, 2008 and 2007 was \$1.0 and \$0.3, respectively.

As of September 30, 2008 and December 31, 2007, our additional paid-in capital pool ("APIC Pool") was \$66.5 and \$63.7, respectively.

-10-

6. EARNINGS PER SHARE (EPS)

Basic earnings per common share excludes dilution and is computed by dividing net earnings by the weighted-average number of common shares outstanding (which includes shares outstanding, less performance and non-vested shares for which vesting criteria have not been met) plus deferred stock awards, weighted for the period outstanding. Diluted earnings per common share is computed by dividing net earnings by the sum of the weighted-average number of common shares outstanding for the period adjusted (i.e., increased) for all additional common shares that would have been outstanding if potentially dilutive common shares had been issued and any proceeds of the issuance had been used to repurchase common stock at the average market price during the period. The proceeds are assumed to be the sum of the amount to be paid to the Company upon exercise of options, the amount of compensation cost attributed to future services and not yet recognized and the amount of income taxes that would be credited to or deducted from capital upon exercise.

The following shows the reconciliation of weighted-average shares:

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2008	2007	2008	2007
Weighted average shares outstanding:	47,818,864	48,186,403	47,925,085	48,166,828
Effect of dilutive shares:				
Options and stock-settled SARS	608,625	1,118,913	745,361	1,055,141
Restricted Stock	12,517	25,267	10,826	24,145
Adjusted average shares outstanding	48,440,006	49,330,583	48,681,272	49,246,114

Outstanding stock options to purchase 70,960 and 35,068 shares of common stock as of September 30, 2008 and 2007, respectively, were excluded from the above calculation because their inclusion would have had an anti-dilutive effect on earnings per share. In addition, 998,885 and 508,945 of outstanding stock-settled SARS as of September 30, 2008 and 2007, respectively, were excluded from the above calculation due to their anti-dilutive effect on earnings per share.

7. INVENTORIES

Edgar Filing: CYTEC INDUSTRIES INC/DE/ - Form 10-Q

Inventories consisted of the following:

	September 30, 2008	December 31, 2007
Finished goods	\$430.1	\$362.1
Work in process	46.7	35.4
Raw materials and supplies	133.0	122.5
Total inventories	\$609.8	\$520.0

8. DEBT

Long-term debt, including the current portion, consisted of the following:

	September 30, 2008		December 31, 2007	
	Face	Carrying Value	Face	Carrying Value
Five-year revolving credit due June 2012	\$ 120.0	\$ 120.0	-	-
6.75% Notes Due March 15, 2008	-	-	100.0	99.0
5.5% Notes Due October 1, 2010	250.0	249.9	250.0	249.9
4.6% Notes Due July 1, 2013	200.0	201.1	200.0	200.0
6.0% Notes Due October 1, 2015	250.0	249.5	250.0	249.5
Other	4.5	4.5	6.3	6.3
	\$ 824.5	\$ 825.0	\$ 806.3	\$ 806.3
Less: Current maturities	(1.5)	(1.5)	(101.5)	(101.5)
Long-term Debt	\$ 823.0	\$ 823.5	\$ 704.8	\$ 704.8

In June 2007, we amended and restated our revolving credit agreement to increase the facility from \$350.0 to \$400.0 and extended the maturity date to June 2012. Borrowings against the \$400.0 unsecured five-year revolving credit facility totaled \$120.0 at September 30, 2008 and none at December 31, 2007. This facility contains covenants that are customary for such facilities.

-11-

The weighted-average interest rate on all of our debt outstanding as of September 30, 2008 and 2007 was 4.96% and 5.01%, respectively. The weighted-average interest rate on short-term borrowings outstanding as of September 30, 2008 and 2007 was 3.88% and 4.69%, respectively.

9. ENVIRONMENTAL, CONTINGENCIES AND COMMITMENTS

Environmental Matters

We are subject to substantial costs arising out of environmental laws and regulations, which include obligations to remove or limit the effects on the environment of the disposal or release of certain wastes or substances at various sites or to pay compensation to others for doing so.

Edgar Filing: CYTEC INDUSTRIES INC/DE/ - Form 10-Q

As of September 30, 2008 and December 31, 2007, the aggregate environmental related accruals were \$99.7 and \$109.7, respectively. As of September 30, 2008 and December 31, 2007, \$7.4 of the above amounts was included in accrued expenses, with the remainder included in other noncurrent liabilities. Environmental remediation spending for the three months ended September 30, 2008 and 2007 was \$1.6 and \$1.0, respectively, and for the nine months ended September 30, 2008 and 2007 was \$3.9 and \$3.1, respectively.

As discussed in note 3, we divested our water treatment and acrylamide product lines to Kemira in 2006 and 2007, including certain manufacturing facilities. At the time of the sale of these facilities Kemira agreed to assume certain related environmental liabilities, and we agreed to compensate Kemira for the estimated costs of required remediation identified in subsequent site evaluations or to undertake such actions on behalf of Kemira. In 2007, we increased our reserves for certain of these sites based on additional information generated by such site evaluations. Negotiations with Kemira over the required remedial actions and their estimated costs were completed in first quarter 2008 and we adjusted our reserves accordingly. We also adjusted our reserves for certain other sites based on new information or changes in remedial plans during the year. Overall, our adjustments resulted in a net increase of \$0.3 and a net reduction of \$0.1 in our environmental accruals for the three and nine months ended September 30, 2008, respectively.

Our environmental related accruals can change substantially due to such factors as additional information on the nature or extent of contamination, methods of remediation required, changes in the apportionment of costs among responsible parties and other actions by governmental agencies or private parties or if we are named in a new matter and determine that an accrual needs to be provided or if we determine that we are not liable and no longer require an accrual.

A further discussion of environmental matters can be found in Note 13 of the Notes to the Consolidated Financial Statements contained in our 2007 Annual Report on Form 10-K.

Other Contingencies

We are the subject of numerous lawsuits and claims incidental to the conduct of our or certain of our predecessors' businesses, including lawsuits and claims relating to product liability, personal injury including asbestos, environmental, contractual, employment and intellectual property matters.

During the third quarter of 2006, we completed a study of our asbestos related contingent liabilities and related insurance receivables. These studies were based on, among other things, detailed data for the previous ten years on the incidence of claims, the incidence of malignancy claims, indemnity payments for malignancy and non-malignancy claims, dismissal rates by claim and estimated future claims. In conjunction with the 2006 asbestos study, we also conducted a detailed update of our previous insurance position and estimated insurance recoveries. We expect to recover close to 54% of our future indemnity costs and certain defense and processing costs already incurred for asbestos claims. We anticipate updating the study approximately every three years or earlier if circumstances warrant. We have completed coverage in place and commutation agreements with several of our insurance carriers and are in the process of negotiating similar agreements with other insurance carriers.

As of September 30, 2008 and December 31, 2007, the aggregate self-insured and insured contingent liability was \$70.7 and \$70.1, respectively, and the related insurance recovery receivable for the liability as well as claims for past payments was \$35.5 at September 30, 2008 and \$37.6 at December 31, 2007. The asbestos liability included in the above amounts at September 30, 2008 and December 31, 2007 was \$53.8 and \$53.9, respectively, and the insurance receivable related to the liability as well as claims for past payments was

Edgar Filing: CYTEC INDUSTRIES INC/DE/ - Form 10-Q

\$33.5 at September 30, 2008 and \$35.6 at December 31, 2007. We anticipate receiving a net tax benefit for payment of those claims for which full insurance recovery is not realized.

-12-

The following table presents information about the number of claimants involved in asbestos claims with us:

	Nine Months Ended September 30, 2008	Year Ended December 31, 2007
Number of claimants at beginning of period	8,200	8,600
Number of claimants associated with claims closed during period	(200)	(700)
Number of claimants associated with claims opened during period	100	300
Number of claimants at end of period	8,100	8,200

Numbers in the foregoing table are rounded to the nearest hundred and are based on information as received by us which may lag actual court filing dates by several months or more. Claims are recorded as closed when a claimant is dismissed or severed from a case. Claims are opened whenever a new claim is brought, including from a claimant previously dismissed or severed from another case.

It should be noted that the ultimate liability and related insurance recovery for all pending and anticipated future claims cannot be determined with certainty due to the difficulty of forecasting the numerous variables that can affect the amount of the liability and insurance recovery. These variables include but are not limited to: (i) significant changes in the number of future claims; (ii) significant changes in the average cost of resolving claims; (iii) changes in the nature of claims received; (iv) changes in the laws applicable to these claims; and (v) financial viability of co-defendants and insurers.

At September 30, 2008, we were among several defendants in approximately 10 cases in the U.S., in which plaintiffs assert claims for personal injury, property damage, and other claims for relief relating to one or more kinds of lead pigment that were used as an ingredient decades ago in paint for use in buildings. The different suits were brought by government entities and/or individual plaintiffs, on behalf of themselves and others. The suits variously seek compensatory and punitive damages and/or injunctive relief, including funds for the cost of monitoring, detecting and removing lead based paint from buildings and for medical monitoring; for personal injuries allegedly caused by ingestion of lead-based paint; and plaintiffs' attorneys' fees. We believe that the suits against us are without merit, and we are vigorously defending against all such claims. We have not recorded a loss contingency for these cases.

In July 2005, the Supreme Court of Wisconsin held in a case in which we were one of several defendants that Wisconsin's risk contribution doctrine applies to bodily injury cases against manufacturers of white lead pigment. Under this doctrine, manufacturers of white lead pigment may be liable for injuries caused by white lead pigment based on their past market shares unless they can prove they are not responsible for the white lead pigment which caused the injury in question. We settled this case for an immaterial amount. Seven other courts have previously rejected the applicability of this and similar doctrines to white

Edgar Filing: CYTEC INDUSTRIES INC/DE/ - Form 10-Q

lead pigment. Although we are a defendant in approximately 5 similar cases in Wisconsin as of September 30, 2008, which are currently stayed, and additional actions may be filed in Wisconsin, we intend to vigorously defend ourselves if such case(s) are filed based on what we believe to be our non-existent or diminutive market share. In October 2007, the Wisconsin Court of Appeals affirmed the trial court's dismissal of the plaintiff's strict liability and negligent design defect causes of action for white lead carbonate in the case styled Ruben Godoy et al v. E.I DuPont de Nemours et al., one of the approximately 5 Wisconsin lead cases. The decision in this case reinforces our belief that our liability, if any, in these cases is immaterial, both individually and in the aggregate, and accordingly no loss contingency has been recorded. In March 2008, the Wisconsin Supreme Court granted plaintiff's petition for certiorari in this case.

We have access to a substantial amount of primary and excess general liability insurance for property damage and believe these policies are available to cover a significant portion of both our defense costs and indemnity costs, if any, for lead pigment related property damage claims. We have agreements with two of our insurers to date which provide that they will pay for approximately fifty percent (50%) of our defense costs associated with lead pigment related property damage claims, and we are in the process of negotiating additional agreements with other insurance carriers.

We commenced binding arbitration proceedings against SNF SA ("SNF") in 2000 to resolve a commercial dispute relating to SNF's failure to purchase agreed amounts of acrylamide under a long-term agreement. In July 2004, the arbitrators awarded us damages and interest aggregating approximately (euro)11.0 plus interest on the award at a rate of 7% per annum from July 28, 2004 until paid. After further proceedings in France, we collected (euro)12.2 (\$15.7) related to the arbitration award including interest in the second quarter of 2006 and recognized the gain in other income in the 2006 consolidated statement of income. Subsequent to the arbitration award, SNF filed a complaint alleging criminal violation of French and European Community antitrust laws relating to the contract which was the subject of the arbitration proceedings, which complaint was dismissed in December 2006. SNF has also filed a final appeal of the court order which allowed us to enforce the award and a separate complaint in France seeking compensation from Cytec for (euro)54.0 in damages it allegedly suffered as a result of our attachment on various SNF receivables and bank accounts to secure enforcement of the arbitration award. We believe that the appeal and complaint are without merit. SNF also appealed the arbitration award in Belgium where the Brussels Court of First Instance invalidated the award in March 2007. We have appealed that decision to the Belgium Court of Appeals, which will review the matter on a de novo basis. The Belgium decision does not affect the enforceability of the award in France, which was subsequently upheld by the Court de Cassation, the highest court in France, in April 2008.

-13-

While it is not feasible to predict the outcome of all pending environmental matters, lawsuits and claims, it is reasonably possible that there will be a necessity for future provisions for costs for environmental matters and for other contingent liabilities that we believe will not have a material adverse effect on our consolidated financial position, but could be material to our consolidated results of operations or cash flows in any one accounting period. We cannot estimate any additional amount of loss or range of loss in excess of the recorded amounts. Moreover, many of these liabilities are paid over an extended period, and the timing of such payments cannot be predicted with any certainty.

From time to time, we are also included in legal proceedings as a plaintiff involving tax, contract, patent protection, environmental and other legal

Edgar Filing: CYTEC INDUSTRIES INC/DE/ - Form 10-Q

matters. Gain contingencies related to these matters, if any, are not recorded until realized.

A further discussion of other contingencies can be found in Note 13 of the Notes to the Consolidated Financial Statements contained in our 2007 Annual Report on Form 10-K.

Commitments

We frequently enter into long-term contracts with customers with terms that vary depending on specific industry practices. Our business is not substantially dependent on any single contract or any series of related contracts. Descriptions of our significant sales contracts at December 31, 2007 are set forth in Note 13 of the Notes to Consolidated Financial Statements contained in our 2007 Annual Report on Form 10-K.

10. COMPREHENSIVE INCOME

The components of comprehensive income, which represents the change in equity from non-owner sources, for the three and nine months ended September 30, 2008 and 2007 are as follows:

	Three Months Ended September 30,		Nine months ended September 30,	
	2008	2007	2008	2007
Net earnings	\$ 46.3	\$ 52.4	\$ 152.0	\$ 152.0
Other comprehensive income (loss):				
Accumulated pension liability, net of tax (1)	(5.9)	(3.0)	(5.8)	(5.8)
Unrealized gains/(losses) on cash flow hedges, net of tax	(18.6)	5.2	(7.2)	(7.2)
Foreign currency translation adjustments	(93.3)	46.4	(32.7)	(32.7)
Comprehensive income	\$ (71.5)	\$ 101.0	\$ 106.3	\$ 106.3

(1) 2007 includes amortization, impacts of a curtailment and remeasurement related to certain U.S. plans, and a settlement in the Netherlands related to the sale of the water treatment and acrylamide product lines. For further details see Note 16 to the Consolidated Financial Statements.

(2) 2007 includes the impact of recognizing \$13.8 in net earnings as a component of the gain on the sale of the water treatment and acrylamide product lines.

Other comprehensive income related to the change in fair value of our cross currency swaps as of December 31, 2007 had previously been reported on a pre-tax basis of \$40.1 in accumulated other comprehensive income on our consolidated balance sheet in our previously filed consolidated financial statements. This has been revised to reflect related tax effects of \$15.9 with a corresponding increase in deferred tax liabilities for the same amount. The tax benefit/(cost) related to unrealized gains/(losses) on our cross currency swaps included in accumulated other comprehensive income in prior periods has been revised accordingly. This revision of prior year financial statements was immaterial and it had no impact on reported net earnings, EPS, or cash flow from operating activities.

11. INCOME TAXES

Edgar Filing: CYTEC INDUSTRIES INC/DE/ - Form 10-Q

The effective income tax rate for the three and nine months ended September 30, 2008 was a tax provision of 33.3% (\$23.1) and 31.9% (\$71.1), respectively, compared to a tax provision of 26.0% (\$18.4) and 27.1% (\$59.1) for the three and nine months ended September 30, 2007. The 2008 effective tax rate for the quarter and year to date was unfavorably impacted by a shift in our earnings to higher tax jurisdictions, and the expiration of the U.S. R&D tax credit effective December 31, 2007. The rate was favorably affected by the incremental accelerated depreciation charge related to our U.S. Pampa facility. Excluding the accelerated depreciation charge discussed above, the underlying estimated annual tax rate for the nine months ended September 30, 2008 was 31.2% excluding accrued interest on unrecognized tax benefits, with an underlying tax rate of 31.7% including such interest.

-14-

On October 3, 2008, the U.S. Government signed into law the Emergency Economic Stabilization Act of 2008 (Division A), the Energy Improvement and Extension Act of 2008 (Division B), and the Tax Extenders and Alternative Minimum Tax Relief Act of 2008 (Division C) (collectively "the Act"). The Act reinstated the U.S. R&D tax credit retroactively to January 1, 2008. However, since this legislation was not officially enacted until October 3, 2008, we excluded the benefits of the U.S. R&D tax credit in our tax provision for three and nine months ended September 30, 2008. The reinstatement of the R&D tax credit will likely reduce our underlying tax rate for ongoing operations to a range of 31.0% to 31.5%.

The 2007 effective rate for the quarter and year to date includes a benefit of \$3.5 as a result of enacted tax legislation that lowered the 2008 German corporate tax rate which led to a corresponding adjustment to our deferred tax liabilities. It also included a French restructuring charge for which no tax benefit was given due to the unlikely utilization of related net operating losses. In addition, the year to date rate was favorably affected by the relatively low tax expense of \$0.4 with respect to a \$15.7 gain recorded on the second phase of the water business divestiture and changes in U.S. tax laws regarding manufacturing incentives.

In January 2008, the Norwegian Supreme Court ("NSC") denied our request to reconsider a tax assessment with respect to a 1999 restructuring of certain European operations. The tax liability attributable to this assessment was approximately 84.0 Norwegian krone (\$14.5). After giving effect for payments previously remitted with respect to this issue, we have a remaining tax liability of Norwegian krone 18.4 (\$3.2) on our balance sheet of which approximately 7.0 Norwegian krone (\$1.2) relates to pre-2005 taxable periods which is expected to be paid within twelve months, with the balance to be paid in subsequently filed tax returns.

In 2006, the state of Maryland assessed a tax deficiency against a U.S. subsidiary asserting nexus with the state. We subsequently filed a judicial notice to proceed to trial with the Maryland Tax Court in opposing the deficiency. In the third quarter of 2008, we settled this case and paid a final assessment of \$1.0 plus accrued interest against a previously recorded liability for this matter.

The amount of unrecognized tax benefits at December 31, 2007 was \$42.4 (gross) of which \$23.9 would impact our effective tax rate, if recognized. As of September 30, 2008, the amount of unrecognized tax benefits is \$39.7 (gross) of which \$19.8 would impact our effective tax rate, if recognized. During the first nine months of 2008, our unrecognized tax benefits were reduced by approximately \$5.2 as result of the aforementioned Norway decision and Maryland settlement, and increased by approximately \$2.5 due to current year tax accruals and the impact of foreign exchange.

Edgar Filing: CYTEC INDUSTRIES INC/DE/ - Form 10-Q

We recognize interest and penalties related to unrecognized tax benefits in income tax expense in the consolidated statements of income. As of December 31, 2007, we had recorded a liability for the payment of interest and penalties, (gross), of approximately \$6.3 which increased by \$0.4 due to current year activity and the impact of foreign exchange, thus resulting in a liability for the payment of interest and penalties of \$6.7 as of September 30, 2008.

12. OTHER FINANCIAL INFORMATION

On July 17, 2008 the Board of Directors declared a \$0.125 per common share cash dividend, paid on August 25, 2008 to shareholders of record as of August 11, 2008. Cash dividends paid in the third quarter of 2008 and 2007 were \$6.0 and \$4.8, respectively, and for the nine months ended September 30, 2008 and 2007 were \$17.9 and \$14.4, respectively. On October 16, 2008 the Board of Directors declared a \$0.125 per common share cash dividend, payable on November 25, 2008 to shareholders of record as of November 10, 2008.

Income taxes paid for the nine months ended September 30, 2008 and 2007 were \$53.0 and \$45.4, respectively. Interest paid for the nine months ended September 30, 2008 and 2007 was \$28.8 and \$31.5, respectively. Interest income for the nine months ended September 30, 2008 and 2007 was \$1.8 and \$1.1, respectively.

-15-

13. SEGMENT INFORMATION

Summarized segment information for our four segments for the three and nine months ended September 30 is as follows:

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2008	2007	2008	2007
Net sales				
Cytec Surface Specialties	\$ 434.0	\$ 413.0	\$ 1,356.6	\$ 1,237.0
Cytec Performance Chemicals				
Sales to external customers	198.9	180.7	583.0	544.6
Intersegment sales	0.3	1.1	1.1	4.8
Cytec Engineered Materials	191.2	162.2	584.5	492.3
Building Block Chemicals				
Sales to external customers	138.9	119.2	417.6	328.7
Intersegment sales	3.6	8.8	15.9	26.8
Net sales from segments	966.9	885.0	2,958.7	2,634.2
Elimination of intersegment revenue	(3.9)	(9.9)	(17.0)	(31.6)
Net sales	\$ 963.0	\$ 875.1	\$ 2,941.7	\$ 2,602.6
		% of sales	% of sales	% of sales
Earnings (loss) from operations				
Cytec Surface Specialties (1)	\$ 22.2	5%	\$ 31.2	8%
			\$ 64.6	5%

Edgar Filing: CYTEC INDUSTRIES INC/DE/ - Form 10-Q

Cytec Performance Chemicals	28.2	14%	18.3	10%	62.9	11%
Cytec Engineered Materials	37.9	20%	28.8	18%	124.2	21%
Building Block Chemicals	(1.3)	-1%	9.4	7%	11.1	3%
	-----		-----		-----	
Earnings from segments	87.0	9%	87.7	10%	262.8	9%
Corporate and Unallocated (2)	(7.2)		(5.6)		(14.3)	
	-----		-----		-----	
Earnings from operations	\$ 79.8	8%	\$ 82.1	9%	\$ 248.5	8%

(1) 2008 includes pre-tax charges of \$1.4 and \$4.2 for the three and nine months ended September 30, 2008, respectively, for incremental accelerated depreciation in relation to our planned exit of Radcure manufacturing assets at our leased facility in Pampa, Texas.

(2) For the three and nine months ended September 30, 2008, Corporate and Unallocated includes pre-tax charges of \$5.7 and \$10.8, respectively, for additional restructuring costs primarily associated with various organizational restructuring initiatives across the Specialty Chemicals segments. In the third quarter of 2007 Corporate and Unallocated includes a net restructuring charge of \$2.8 for costs related to the shut down of a manufacturing facility in France and restructuring of our polymer additive manufacturing facility in Willow Island and our liquid coating resins manufacturing facility in Wallingford. For nine months 2007, Corporate and Unallocated includes a restructuring charge of \$5.4 for the aforementioned items and a \$15.7 gain as a result of completion of the second phase of the sale of our water treatment chemicals and acrylamide product lines to Kemira.

14. GOODWILL AND OTHER ACQUISITION INTANGIBLES

The following is the activity in the goodwill balances for each segment.

	Cytec Performance Chemicals		Cytec Surface Specialties	Cytec Engineered Materials		Corporate	Total	
Balance, December 31, 2007	\$	93.3	\$	769.7	\$	241.1	\$	1,100.7
Currency exchange		(5.3)		(7.6)		-		(12.9)
Balance, September 30, 2008	\$	88.0	\$	762.1	\$	241.1	\$	1,091.2

-16-

Other acquisition intangibles consisted of the following major classes:

	Weighted average useful life (years)	Gross carrying value		Accumulated amortization		
		September 30, 2008	December 31, 2007	September 30, 2008	December 31, 2007	September 30, 2008
Technology-based	15.1	\$ 55.7	\$ 57.2	\$ (27.4)	\$ (25.1)	\$ 28.2
Marketing-related	<2.0	2.1	2.1	(2.1)	(2.1)	0.0

Edgar Filing: CYTEC INDUSTRIES INC/DE/ - Form 10-Q

Marketing-related	15.5	65.2	65.7	(20.5)	(17.7)
Marketing-related	40.0	47.9	48.9	(2.7)	(1.8)
Customer-related	15.0	444.8	449.9	(113.7)	(92.6)

Total		\$ 615.7	\$ 623.8	\$ (166.4)	\$ (139.3)
=====					

Amortization of acquisition intangibles for the three months ended September 30, 2008 and 2007 was \$10.0 and \$9.7, respectively, and for the nine months ended September 30, 2008 and 2007 was \$30.4 and \$28.6, respectively. Assuming no change in the gross carrying amount of acquisition intangibles and the currency exchange rates remain constant, the estimated amortization of acquisition intangibles for the fiscal years 2008 and 2009 is \$40.5, for the years 2010 and 2011 is \$40.4, and for the years 2012 and 2013 is \$40.3 and \$39.5, respectively.

15. DERIVATIVE FINANCIAL INSTRUMENTS AND COMMODITY HEDGING ACTIVITIES

Derivative Financial Instruments

We periodically enter into currency forward contracts primarily to hedge currency fluctuations of transactions denominated in currencies other than the functional currency of the respective entity. At September 30, 2008, the principal transactions hedged involved accounts receivable, accounts payable and intercompany loans. When hedging currency exposures, our practice is to hedge such exposures with forward contracts denominated in the same currency and with similar critical terms as the underlying exposure, and therefore, the instruments are effective at generating offsetting changes in the fair value, cash flows or future earnings of the hedged item or transaction.

At September 30, 2008, net contractual amounts of forward contracts outstanding translated into U. S. dollar amounts of \$80.8. Of this total, \$68.1 was attributed to the net exposure in forward selling of U.S. dollars. The remaining \$12.7 was the net exposure in forward selling of Euros, translated into U. S. dollar equivalent amounts. The net (unfavorable)/favorable fair values of currency contracts, based on forward exchange rates at September 30, 2008 and December 31, 2007 were \$(2.3) and \$1.3, respectively.

We use cross currency swaps to hedge the changes in the cash flows of certain Euro denominated intercompany loans receivable (Euro loans) held by U.S. entities. The loan amounts are (euro)207.9 and (euro)207.9 due October 1, 2010 and October 1, 2015, respectively. Because the Euro loans are denominated in Euros, we have foreign exchange exposure upon remeasurement to the U.S. dollar ("USD"). We hedged this foreign exchange exposure by entering into cross currency swaps with notional amounts of (euro)207.9 (\$250.0) that settle on October 1, 2010 and October 1, 2015, respectively. At the initial principal exchange, we paid \$500.0 and received (euro)415.8 from counterparties. At the final exchanges we will pay (euro)207.9 and receive \$250.0 on October 1, 2010 and October 1, 2015. The swaps have fixed interest rates on both legs. On the five year swaps, we pay 3.78% interest per annum on the Euro notional amount and we receive 5.5% interest per annum on the USD notional amount. On the ten year swaps, we pay 4.52% interest per annum on the Euro notional amount and we receive 6.0% interest per annum on the USD notional amount. The interest payment dates (April 1 and October 1) and Euro rates coincide with the Euro loans.

The swaps fix the U.S. dollar equivalent cash flows of the Euro loans and eliminate foreign exchange variability since the notional amounts of the swaps equal that of the loans, and all cash flow dates and interest rates coincide between the swaps and the loans, therefore no ineffectiveness is expected. These swaps have been designated as cash flow hedges. Each period we record the change in the swaps' fair value, net of income taxes to accumulated other comprehensive income. We reclassify an amount out of accumulated other comprehensive income to

Edgar Filing: CYTEC INDUSTRIES INC/DE/ - Form 10-Q

the income statement equal to the foreign currency gain or loss on the remeasurement to USD of the Euro loans which offsets the foreign currency gain or loss. We also accrue for the periodic net swap payments each period in the income statement. We monitor the counterparty credit risk and the continued probability of the hedged cash flows as to amount and timing.

At September 30, 2008, the unfavorable fair values of the five and ten year swaps were \$36.0 and \$25.0, respectively, and at December 31, 2007, the unfavorable fair values of the five and ten year swaps were \$39.8 and \$31.4, respectively. As long as the Euro loans remain outstanding, we will reclassify amounts out of accumulated other comprehensive income to the income statement to offset the amount of foreign exchange gain or loss on the remeasurement of the Euro loans recorded each period. The amount of such reclassification will depend on changes in the USD/Euro exchange rate occurring during the period. There were no amounts reclassified out of accumulated other comprehensive income during the nine months ended September 30, 2008 and during the fiscal year 2007 relating to discontinuance of this hedging relationship.

-17-

Commodity Hedging Activities

At September 30, 2008, we held natural gas swaps with an unfavorable fair value of \$10.5 included in accrued expenses, which will be reclassified into Manufacturing Cost of Sales through September 2009 as the hedged natural gas purchases affect earnings.

Fair Value Measurements

On January 1, 2008 we adopted SFAS 157 for financial assets and liabilities, as well as for any other assets and liabilities that are carried at fair value on a recurring basis in financial statements. Under SFAS 157, a company must determine the appropriate level in the fair value hierarchy for each fair value measurement. The fair value hierarchy in SFAS 157 prioritizes the inputs, which refer broadly to assumptions market participants would use in pricing an asset or liability, into three levels. It gives the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The level in the fair value hierarchy within which a fair value measurement in its entirety falls is determined based on the lowest level input that is significant to the fair value measurement in its entirety. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Level 2 inputs are inputs other than quoted prices within Level 1 that are observable for the asset or liability, either directly or indirectly, such as quoted prices for similar assets or liabilities in active markets, interest rates, exchange rates, and yield curves observable at commonly quoted intervals. Level 3 inputs are unobservable inputs for the asset or liability.

All of our derivatives are valued based on level 2 inputs. Our gas swaps and currency forwards are valued based on readily available published indices for commodity prices and currency exchange rates. Our cross currency swaps are valued using an income approach based on industry-standard techniques. This model includes a discounted cash flow analysis that nets the discounted future cash receipts and the discounted expected cash payments resulting from the swap. The analysis is based on the contractual terms of the swaps including the period to maturity and observable market-based inputs that include time value, interest rate curves, foreign exchange rates, implied volatilities, as well as other relevant economic measures. We incorporate credit valuation adjustments to appropriately reflect both our own nonperformance risk and the counterparty's nonperformance risk in the fair value measurements.

Edgar Filing: CYTEC INDUSTRIES INC/DE/ - Form 10-Q

Although we have determined that the majority of the inputs used to value our derivatives fall within Level 2 of the fair value hierarchy, the credit valuation adjustments associated with our derivatives utilize Level 3 inputs, such as estimates of current credit spreads, to evaluate the likelihood of default by us and our counterparties. However, as of September 30, 2008, we have assessed the significance of the impact of the credit valuation adjustments on the overall valuation of our derivative positions and have determined that the credit valuation adjustments are not significant to the overall valuation of our derivatives. As a result, we have determined that our derivative valuations in their entirety are classified in Level 2 of the fair value hierarchy.

A summary of the fair value measurements for each major category of derivatives is outlined in the table below:

Description	September 30, 2008 Total	Significant Other Observable Inputs (Level 2)
Currency forwards	\$(2.3)	\$(2.3)
Cross currency swap	(61.0)	(61.0)
Natural gas swap	(10.5)	(10.5)
Total	\$(73.8)	\$(73.8)

As of September 30, 2008, we did not have any non-financial assets and liabilities that are carried at fair value on a recurring basis in the financial statements. For more information regarding our hedging activities and derivative financial instruments, refer to Note 8 to the Consolidated Financial Statements contained in our 2007 Annual Report on Form 10-K.

-18-

16. EMPLOYEE BENEFIT PLANS

Net periodic cost for our pension and postretirement benefit plans was as follows:

	Pension Plans		Postretirement Plans	
	Three Months Ended September 30,			
	2008	2007	2008	2007
Service cost	\$ 2.6	\$ 4.5	\$ 0.3	\$ 0.3
Interest cost	12.1	10.4	3.0	3.0
Expected return on plan assets	(11.6)	(11.6)	(1.0)	(0.8)
Net amortization and deferral	4.4	3.1	(2.6)	(2.5)
Net periodic cost	\$ 7.5	\$ 6.4	\$ (0.3)	\$ 0.0
=====				
	Nine months ended September 30,			
	2008	2007	2008	2007
	\$ 7.9	\$ 14.6	\$ 0.9	\$ 0.9
Interest cost	35.7	32.8	9.1	10.2

Edgar Filing: CYTEC INDUSTRIES INC/DE/ - Form 10-Q

Expected return on plan assets	(35.7)	(33.4)	(3.0)	(3.2)
Net amortization and deferral	9.5	11.0	(7.8)	(7.7)
Curtailments/settlements (1)	-	3.3	-	-
	-----	-----	-----	-----
Net periodic cost	\$ 17.4	\$ 28.3	\$ (0.8)	\$ 0.2
=====				

- (1) Primarily represents a settlement charge related to the transfer of plan assets and liabilities in the Netherlands related to the sale of the water treatment and acrylamide product lines, which was charged against the gain on sale.

We disclosed in our 2007 Annual Report on Form 10-K that we expected to contribute \$32.6 and \$16.6, respectively, to our pension and postretirement plans in 2008. Through September 30, 2008, \$18.0 and \$11.2 in contributions were made, respectively.

In September 2008, using updated demographic data, our actuaries revised the estimated funded status of our U.S. pension plans as of January 1, 2008, as well as the related 2008 pension expense. As a result, we recorded a charge of \$2.4 to our third quarter 2008 consolidated statement of income to reflect the year-to-date increase in expense, and we also recorded an increase of \$9.5 to our U. S. pension liabilities, with a corresponding decrease of \$5.8 in accumulated other comprehensive income ("AOCI") and an adjustment to deferred taxes for \$3.7 to reflect the revised funded status.

In March 2007, we announced a change to our U.S. salaried pension plans from defined benefit plans to defined contribution plans effective December 31, 2007. A related plan curtailment was estimated and recorded in the first quarter 2007, and adjusted later in the year, resulting in a decrease in our pension liabilities of \$12.2, with a corresponding increase in AOCI of \$7.5 and an adjustment to deferred taxes of \$4.7. The curtailment had an immaterial effect on our 2007 consolidated statement of income. We considered these plan changes to be significant events as contemplated by SFAS No. 158, "Employers' Accounting for Defined Benefit Pension and Other Postretirement Benefits, an amendment of SFAS 87, 88, 106 and 132(R)" ("SFAS 158") and accordingly, the liabilities and assets for the affected plans were remeasured as of March 31, 2007. The remeasurement resulted in a further decrease to pension liabilities of approximately \$6.1, with a corresponding increase of \$3.7 in AOCI, and an adjustment to deferred taxes for \$2.4. The remeasurement was driven by a change in the discount rate assumption for the affected plans (from 5.85% at December 31, 2006 to 6.00% at March 31, 2007), and slightly better than expected returns on plan assets for the three months ended March 31, 2007. Finally, in September 2007, using updated demographic data, our actuaries revised the estimated funded status of our U.S. pension plans as of January 1, 2007. As a result, we recorded an increase of \$6.8 to our U.S. pension liabilities, with a corresponding decrease of \$4.1 in AOCI and an adjustment to deferred taxes for \$2.7, to reflect the funded status at January 1, 2007 as determined by the actuarial valuation.

In September 2006, the FASB issued SFAS No. 158, "Employers' Accounting for Defined Benefit Pension and Other Postretirement Benefits, an amendment of SFAS 87, 88, 106 and 132(R)" ("SFAS 158"), which we adopted in the fourth quarter of 2006 except for the measurement date requirement. Until January 1, 2008, we used a measurement date of November 30 for the majority of our non-U.S. defined benefit pension plans. The provisions of SFAS 158 requiring that the measurement date be the same as the date of the consolidated balance sheet became effective as of January 1, 2008 and requires us to change our measurement date for certain non-U.S. defined benefit pension plans to December 31 from November 30. SFAS 158 allows employers to choose one of two transition methods to adopt the measurement date requirement. We chose to adopt the measurement date requirement

Edgar Filing: CYTEC INDUSTRIES INC/DE/ - Form 10-Q

in 2008 using the 13-month approach. Under this approach, we will record an additional one month of net periodic benefit cost covering the period between the previous measurement date of November 30, 2007 and December 31, 2007 as an adjustment to equity in the fourth quarter of 2008. We do not expect the adjustment to equity to have a material impact on our consolidated financial statements.

-19-

We also sponsor various defined contribution retirement plans in the United States and a number of other countries, consisting primarily of savings and profit growth sharing plans. In conjunction with the above mentioned change to our U.S. salaried pension plans, we discontinued the U.S. profit growth sharing plan effective December 31, 2007 for all U.S. salaried and nonbargaining unit employees. All such employees participated in an enhanced savings plan effective on the same date. Contributions to the savings plans are based on matching a percentage of employees' contributions. Contributions to the profit growth sharing plans are generally based on our financial performance. Amounts expensed related to these plans for the three months ended September 30, 2008 and 2007 were \$6.4 and \$4.2, respectively, and for the nine months ended September 30, 2008 and 2007 were \$21.4 and \$15.2, respectively.

-20-

Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis should be read in conjunction with the Consolidated Financial Statements and Notes to Consolidated Financial Statements. Currency amounts are in millions, except per share amounts. Percentages are approximate.

GENERAL

We are a global specialty chemicals and materials company and sell our products to diverse major markets for aerospace, adhesives, automotive and industrial coatings, chemical intermediates, inks, mining and plastics. We operate in four major segments: Cytec Surface Specialties, Cytec Performance Chemicals, Cytec Engineered Materials and Building Block Chemicals. Sales price and volume by region and the impact of exchange rates on our reporting segments are important measures that are analyzed by management and are provided in our segment analysis.

In the course of our ongoing operations, a number of strategic product line acquisitions and dispositions have been made. The results of operations of the acquired businesses have been included in our consolidated results from the dates of the respective acquisitions.

We also report net sales in four geographic regions: North America, Latin America, Asia/Pacific and Europe/Middle East/Africa. The destination of the sale determines the region under which it is reported consistent with management's view of the business. North America consists of the United States and Canada. Latin America includes Mexico, Central America, South America and the Caribbean Islands. Asia/Pacific is comprised of Asia, Australia and the islands of the South Pacific Rim.

Raw material cost changes year on year are an important factor in profitability especially in years of high volatility. Global oil and natural gas costs in certain countries are highly volatile and many of our raw materials are derived from these two commodities. Discussion of the year to year impact of raw

Edgar Filing: CYTEC INDUSTRIES INC/DE/ - Form 10-Q

materials and energy is provided in our segment discussion. In addition, higher global demand levels and, occasionally, operating difficulties at suppliers, have limited the availability of certain of our raw materials.

Quarter Ended September 30, 2008, Compared With Quarter Ended September 30, 2007

Consolidated Results

Net sales for the third quarter of 2008 were \$963.0 compared with \$875.1 for the third quarter of 2007. Overall, sales were up 10% with volumes declining 4%, price increases of 10%, and changes in exchange rates increasing sales 4%. Cytec Surface Specialties sales were up 5% primarily due to the favorable impact of exchange rate changes and higher selling prices partially offset by lower volumes. Cytec Performance Chemicals sales were up 10% primarily due to higher selling prices and changes in exchange rates partially offset by slightly lower volumes. Cytec Engineered Materials sales were up 18% primarily due to higher volumes and selling price increases. Building Block Chemicals sales increased 17% primarily due to higher selling prices partially offset by lower volumes.

For a detailed discussion on revenues refer to the Segment Results section below.

Manufacturing cost of sales was \$765.8 or 79.5% of sales in the third quarter of 2008, compared with \$683.8, or 78.1% of sales in the third quarter of 2007. The \$82.0, or 1.4% increase in manufacturing cost as a percent of sales, is primarily due to \$78.4 of higher raw material prices, \$11.9 due to higher manufacturing costs primarily due to inflation, and \$24.8 due to changes in exchange rates partially offset by \$25.6 due to the lower selling volumes and \$7.9 related to higher fixed cost absorption into inventory as production exceeded demand. The third quarter of 2008 includes \$1.4 of incremental accelerated depreciation on assets at our Pampa, Texas site that we have decided to exit and consolidate production. The third quarter of 2008 includes a restructuring charge of \$1.5 primarily related to restructuring our Specialty Chemical segments. The third quarter of 2007 includes a restructuring charge of \$2.7 related to our Specialty Chemical segments. See Note 4 to the consolidated financial statements for additional detail.

Selling and technical services was \$57.4 in the third quarter of 2008 versus \$52.3 in the third quarter of 2007. Most of the increase was due to inflationary costs, changes in exchange rates of \$1.9, and restructuring costs of \$2.7.

Research and process development was \$19.2 versus \$18.0 in the prior year which includes increased technology spending of \$0.8 in our Cytec Engineered Materials segment and changes in exchange rates of \$0.6.

Administrative and general expenses were \$30.8 versus \$29.2 in the prior year. The increase is primarily attributable to restructuring costs of \$1.4 and changes in exchange rates of \$1.0.

-21-

Amortization of acquisition intangibles was \$10.0 in the third quarter of 2008 versus \$9.7 in the third quarter of 2007 with the increase due to changes in exchange rates.

Other income (expense), net was expense of \$2.1 in the third quarter of 2008 compared with expense of \$1.4 in the third quarter of 2007. The increase in expense is primarily due to unfavorable foreign currency transaction exchange of \$0.4 and increased legal spending of \$0.7 versus the third quarter of 2007.

Equity in earnings of associated companies was \$0.4 versus \$0.5 in the prior

Edgar Filing: CYTEC INDUSTRIES INC/DE/ - Form 10-Q

year.

Interest expense, net was \$8.7 compared with \$10.4 in the prior year. The decrease resulted primarily from lower average outstanding debt balances and lower cost of borrowing versus 2007.

The effective tax rate for the quarter ended September 30, 2008 was a tax provision of 33.3% (\$23.1) compared to 26.0% (\$18.4) for the quarter ended September 30, 2007. The 2008 effective tax rate was unfavorably impacted by a shift in our earnings to higher tax jurisdictions and the expiration of the U.S. R&D tax credit effective December 31, 2007. The rate was favorably affected by the incremental accelerated depreciation charge related to our U.S. Pampa facility. Excluding the impact of the accelerated depreciation charge discussed above, the underlying estimated annual tax rate for the quarter ended September 30, 2008 was 31.2% excluding accrued interest on unrecognized tax benefits, with an underlying tax rate of 31.7% including such interest.

On October 3, 2008, the U.S. Government signed into law the Emergency Economic Stabilization Act of 2008 (Division A), the Energy Improvement and Extension Act of 2008 (Division B), and the Tax Extenders and Alternative Minimum Tax Relief Act of 2008 (Division C) (collectively "the Act"). The Act reinstated the U.S. R&D tax credit retroactively to January 1, 2008. However, since this legislation was not officially enacted until October 3, 2008, we excluded the benefits of the U.S. R&D tax credit in our tax provision for three months ended September 30, 2008. The reinstatement of the R&D tax credit will likely reduce our underlying tax rate for ongoing operations to a range of 31.0% to 31.5%.

The effective tax rate for the quarter ended September 30, 2007 includes a benefit of \$3.5 as a result of enacted tax legislation that lowered the 2008 German corporate tax rate which led to a corresponding adjustment to our deferred tax liabilities. Partially offsetting this benefit was a French restructuring charge for which no tax benefit was given due to the unlikely utilization of related net operating losses. Excluding the impact of these two items, the underlying rate for the three months ended September 30, 2007 was 29.7% excluding accrued interest on unrecognized tax benefits, with an underlying rate of 30.25% including such interest.

Net earnings for the third quarter of 2008 were \$46.3 (\$0.96 per diluted share), a \$6.1 decrease from net earnings of \$52.4 (\$1.06 per diluted share) in the same period in 2007. Included in the third quarter of 2008 was \$4.0 of after-tax restructuring costs primarily related to our Surface Specialties segment and a \$0.9 after-tax charge related to incremental accelerated depreciation on our Pampa, Texas Surface Specialties manufacturing site that we have decided to exit and relocate the manufacturing to one of our other existing facilities. Included in the third quarter of 2007 was \$2.8 after-tax restructuring charge principally related to manufacturing costs of sales with \$1.3 related to restructuring of our Performance Chemicals polymer additive manufacturing operations in West Virginia, \$0.8 related to restructuring our Surface Specialties liquid coating resins manufacturing facility in Connecticut and \$0.7 related to the shutdown of our Surface Specialties manufacturing operations in Dijon, France facility.

Segment Results

In accordance with our policy for segment reporting, restructuring costs are included in our corporate and unallocated operating results consistent with management's view of its businesses.

Year-to-year comparisons and analyses of changes in net sales to external customers by product line segment and region are set forth below.

Cytec Surface Specialties

Edgar Filing: CYTEC INDUSTRIES INC/DE/ - Form 10-Q

	2008	2007	Total % Change	% Change Due to		
				Price	Volume/Mix	Currency
North America	\$89.0	\$89.0	-	9%	-9%	-
Latin America	20.9	18.1	15%	7%	2%	6%
Asia/Pacific	85.7	72.6	18%	7%	4%	7%
Europe/Middle East/Africa	238.4	233.3	2%	-	-7%	9%
Total	\$434.0	\$413.0	5%	3%	-5%	7%

-22-

Overall sales were up 5%. Selling volumes declined 5% with volumes up in Latin America and Asia/Pacific but were more than offset by declines in North America and Europe where we experienced weaker demand especially in the automotive and construction market sectors. Volumes were down in all product lines except Radcure which was flat. Overall selling prices were up 3% with increases in all product lines except powders where they were flat primarily due to price competition. Changes in exchange rates increased sales by 7%.

Earnings from operations were \$22.2, or 5% of sales in 2008, down from \$31.2, or 8% of sales, in 2007. Earnings were positively impacted \$14.0 due to higher selling prices, \$2.5 by changes in exchange rates, and \$1.3 due to higher fixed cost absorption into inventory due to the lower demand at the end of the quarter. Earnings were negatively impacted \$15.4 due to higher raw material costs, \$8.6 due to lower selling volumes, \$1.3 higher manufacturing and operating costs, and \$1.4 of incremental accelerated depreciation on assets at our Pampa, Texas site that we have decided to exit and consolidate production.

Cytec Performance Chemicals

	2008	2007	Total % Change	% Change Due to		
				Price	Volume/Mix	Currency
North America	\$68.9	\$65.7	5%	7%	-2%	-
Latin America	32.9	31.8	3%	12%	-10%	1%
Asia/Pacific	39.0	30.7	27%	18%	6%	3%
Europe/Middle East/Africa	58.1	52.5	11%	6%	-3%	8%
Total	\$198.9	\$180.7	10%	9%	-2%	3%

Overall sales increased 10%. Selling volumes decreased 2% with lower volume across all businesses except mining chemicals which had a 16% increase due to continued strong demand, sales of new products and new business. Selling volumes were down in all regions except Asia/Pacific where we had strong mining chemical sales. Overall selling prices increased 9% with increases across all product lines and regions. Changes in exchange rates increased sales by 3%.

Earnings from operations were \$28.2, or 14% of sales in 2008, up from \$18.3, or

Edgar Filing: CYTEC INDUSTRIES INC/DE/ - Form 10-Q

10% in 2007. Earnings were positively impacted \$16.7 by higher selling prices, \$0.5 by positive product mix, \$2.1 due to higher fixed cost absorption into inventory principally due to the timing of production campaigns, \$0.9 due to lower operating costs, and \$1.5 due to changes in exchange rates. Earnings were negatively impacted \$11.6 due to higher raw material costs.

Cytec Engineered Materials

	2008	2007	Total % Change	% Change Due to		
				Price	Volume/Mix	Currency
North America	\$117.4	\$104.9	12%	2%	10%	-
Latin America(1)	0.4	0.2	-	-	-	-
Asia/Pacific	14.6	12.9	13%	-	13%	-
Europe/Middle East/Africa	58.8	44.2	33%	4%	29%	-
Total	\$191.2	\$162.2	18%	3%	15%	-

(1) Due to the level of sales in this geographic region, percentage comparisons are not meaningful.

Overall sales were up 18% primarily due to a 15% increase in selling volumes with increases in all regions and across most market sectors principally lead by volume increases in the business/regional jet and large commercial aircraft sectors. Selling prices were up 3% overall with increases across most market sectors and regions.

Earnings from operations were \$37.9 or 20% of sales in 2008, up from \$28.8, or 18% of sales in 2007. The \$9.1 increase in earnings was positively impacted \$13.0 due to higher volumes, \$4.2 due to higher selling prices, and \$1.7 due to higher fixed cost absorption into inventory due to increased production levels. Earnings were negatively impacted by \$1.5 due to higher raw material costs, \$6.8 due to higher manufacturing costs primarily related to the higher production volumes, and \$1.0 due to higher operating costs primarily related to increased investments in research and development. Earnings were negatively impacted \$0.5 due to changes in exchange rates.

-23-

Building Block Chemicals

	2008	2007	Total % Change	% Change Due to		
				Price	Volume/Mix	Currency
North America	\$109.1	\$65.6	66%	73%	-7%	-
Latin America(1)	1.7	1.3	-	-	-	-
Asia/Pacific	-	11.7	-100%	-	-100%	-
Europe/Middle East/Africa	28.1	40.6	-31%	19%	-50%	-
Total	\$138.9	\$119.2	17%	47%	-30%	-

(1) Due to the level of sales in this geographic region, percentage comparisons

Edgar Filing: CYTEC INDUSTRIES INC/DE/ - Form 10-Q

are not meaningful.

Overall sales increased 17% primarily due to higher selling prices of 47% to offset raw material price increases. Overall selling volumes were down 30% primarily due to significantly lower acrylonitrile volumes. We are seeing demand destruction in acrylic fibers primarily in Asia and Europe due to high costs for acrylonitrile. In North America, selling volumes were impacted by weak demand and the effect of hurricane activity on our customers.

Loss from operations was \$1.3 compared to earnings of \$9.4 or 8% of sales in 2007. Loss was positively impacted by a \$56.0 increase in selling prices and \$3.0 of higher fixed cost absorption into inventory due to higher production than demand primarily in the acrylonitrile product line. Earnings in 2008 were negatively impacted \$50.0 due to higher raw material costs, \$15.7 related to lower selling volumes, and \$4.3 of higher manufacturing costs primarily due to lower acid regeneration operations and costs related to hurricane Gustav.

Nine months ended September 30, 2008, Compared With Nine months ended September 30, 2007

Consolidated Results

Net sales for the first nine months of 2008 were \$2,941.7 compared with \$2,602.6 for the prior year period. Overall, sales were up 13% with volumes up 1%, price increases of 7%, and changes in exchange rates increasing sales 5%. In the Cytec Surface Specialties segment, sales increased 10% primarily as a result of changes in exchange rates and selling price increases partially offset by lower selling volumes. The Cytec Performance Chemicals segment sales increased 7% due to higher selling prices and changes in exchange rates partially offset by lower selling volumes due to the completion of a resale agreement related to the sale of the water treating chemicals product line in the prior year period. In Cytec Engineered Materials segment, sales increased 19% primarily due to higher selling volumes and prices. Building Block Chemical segment sales were up 27% primarily due to higher selling prices partially offset by lower volumes.

For a detailed discussion on sales refer to the Segment Results section below.

Manufacturing cost of sales was \$2,334.6 or 79.4% of sales for the first nine months of 2008 compared with \$2,045.6 or 78.6% of sales for the first nine months of 2007. The \$289.0 increase in manufacturing costs, or 0.8% increase in manufacturing cost as a percent of sales, is primarily due to \$163.0 of higher raw material prices, \$112.0 due to changes in exchange rates, and \$40.6 related to higher fixed costs due to inflationary increases. These increases were partially offset by \$11.4 of higher fixed cost absorption into inventory as production exceeded demand and \$13.6 of lower costs related to the completion of the resale agreement for the divestiture of the water treatment product line in the prior year period. The first nine months of 2008 includes \$4.2 of incremental accelerated depreciation on assets at our Pampa, Texas site that we have decided to exit and consolidate production. Included in the first nine months of 2008 was a \$5.0 pre-tax restructuring charge primarily related to restructuring charges for various organization restructuring initiatives across both Specialty Chemical segments and restructuring costs at our West Virginia, Connecticut, and French manufacturing operations. Included in the first nine months of 2007 was a \$5.0 pre-tax restructuring charge primarily related to restructuring of our French, West Virginia, and Connecticut manufacturing operations. See Note 4 to the consolidated financial statements for additional detail.

Selling and technical services was \$176.1 in the first nine months of 2008 versus \$155.3 in the first nine months of 2007. Most of the increase was due to inflation, exchange rate changes of \$9.3, increased spending in our Cytec Engineered Materials segment related to the higher demand levels of \$4.2, and a

Edgar Filing: CYTEC INDUSTRIES INC/DE/ - Form 10-Q

restructuring charge of \$3.5.

Research and process development was \$62.5 versus \$55.5 in the prior year with most of the increase due to inflation, exchange rate changes of \$3.0, higher spending in the Cytec Engineered Materials segment of \$3.2, and a restructuring charge of \$0.6.

Administrative and general expenses were \$89.6 versus \$84.4 in the prior year with most of the increase due to inflation, exchange rate changes of \$4.6, and a restructuring charge of \$1.7. The first nine months of 2007 includes a net restructuring charge of \$0.4 for administrative and general.

-24-

Amortization of acquisition intangibles was \$30.4 in the first nine months of 2008 versus \$28.6 in the first nine months of 2007 with the increase due to changes in exchange rates.

In the first nine months of 2007 the gain on sale of assets held for sale of \$15.7 was attributable to the phase two closing of the water treatment and acrylamide product lines. See Note 3 of the Consolidated Financial Statements for further information.

Other income (expense), net was income of \$1.0 in the first nine months of 2008 compared with income of \$0.1 in the first nine months of 2007. The increase is primarily due to favorable foreign currency transaction exchange, partially offset by increased legal spending versus the first nine months of 2007.

Equity in earnings of associated companies was \$1.4 in the first nine months of 2008 versus \$0.9 in the first nine months of 2007.

Interest expense, net was \$27.8 in the first nine months of 2008 compared with \$31.9 in the first nine months of 2007. The decrease resulted primarily from lower average outstanding debt balances and lower cost of borrowing versus 2007.

The effective tax rate for the nine months ended September 30, 2008 was a tax provision of 31.9% (\$71.1) compared to 27.1% (\$59.1) for the nine months ended September 30, 2007. The effective tax rate for the nine months ended September 30, 2008 was unfavorably impacted by a shift in our earnings to higher tax jurisdictions, and the expiration of the U.S. R&D tax credit effective December 31, 2007. The effective tax rate was favorably affected by the incremental accelerated depreciation charge related to our U.S. Pampa facility. Excluding the accelerated depreciation charge discussed above, the underlying estimated annual tax rate for the nine months ended September 30, 2008 was 31.2% excluding accrued interest on unrecognized tax benefits, with an underlying tax rate of 31.7% including such interest.

On October 3, 2008, the U.S. Government signed into law the Emergency Economic Stabilization Act of 2008 (Division A), the Energy Improvement and Extension Act of 2008 (Division B), and the Tax Extenders and Alternative Minimum Tax Relief Act of 2008 (Division C) (collectively "the Act"). The Act reinstated the U.S. R&D tax credit retroactively to January 1, 2008. However, since this legislation was not officially enacted until October 3, 2008, we excluded the benefits of the U.S. R&D tax credit in our tax provision for nine months ended September 30, 2008. The reinstatement of the R&D tax credit will likely reduce our underlying tax rate for ongoing operations to a range of 31.0% to 31.5%.

The effective tax rate for the nine months ended September 30, 2007 includes a benefit of \$3.5 as a result of enacted tax legislation that lowered the 2008 German corporate tax rate which led to a corresponding adjustment to our deferred tax liabilities. Partially offsetting this benefit was a French

Edgar Filing: CYTEC INDUSTRIES INC/DE/ - Form 10-Q

restructuring charge for which no tax benefit was given due to the unlikely utilization of related net operating losses. In addition, the effective tax rate was favorably affected by the relatively low tax expense of \$0.4 with respect to a \$15.7 gain recorded in the first quarter of 2007 on the second phase of the water business divestiture and changes in U.S. tax laws regarding manufacturing incentives. Excluding these items, the underlying estimated annual tax rate for the nine months ended September 30, 2007 was 29.7% excluding accrued interest on unrecognized tax benefits, with an underlying rate of 30.25% including such interest.

Net earnings for the first nine months of 2008 were \$152.0 (\$3.12 per diluted share) compared with net earnings for 2007 of \$158.9 (\$3.23 per diluted share). Included in the first nine months of 2008 was a \$7.6 after-tax restructuring charge for various organizational restructuring initiatives across both Surface Specialties and Performance Chemical segments and restructuring costs at our Performance Chemicals manufacturing facility in West Virginia and Surface Specialties manufacturing facilities in Connecticut and France. Included in our 2008 results was a \$2.7 after-tax charge related to incremental accelerated depreciation on our Pampa, Texas Surface Specialties manufacturing site that we have decided to exit and relocate the manufacturing to one of our other existing facilities. Included in the first nine months of 2007 was \$4.8 after-tax expense of restructuring costs primarily related to restructuring of our Surface Specialties manufacturing operations in France and Connecticut and Performance Chemical manufacturing operations located in West Virginia, as well as a \$15.3 after-tax gain related to the second phase of the sale of our water treatment chemicals and acrylamide product lines to Kemira.

Segment Results

In accordance with our policy for segment reporting, restructuring costs are included in our corporate and unallocated operating results consistent with management's view of its businesses.

Year-to-year comparisons and analyses of changes in net sales to external customers by product line segment and region are set forth below.

-25-

Cytec Surface Specialties

	2008	2007	Total % Change	% Change Due to		
				Price	Volume/Mix	Currency
North America	\$269.7	\$269.1	-	5%	-5%	-
Latin America	59.8	52.6	14%	-	5%	9%
Asia/Pacific	246.0	205.6	20%	3%	7%	10%
Europe/Middle East/Africa	781.1	709.7	10%	-	-3%	13%
Total	\$1,356.6	\$1,237.0	10%	2%	-2%	10%

Overall sales were up 10%. Sales volumes were up in Latin America and Asia/Pacific but were more than offset by declines in North America and Europe where we experienced weaker demand especially in the automotive and construction market sectors. Volumes were down in all product lines except Radcure which was up 3%. Overall selling prices increased 2% with higher prices in liquid coating resins and flat pricing in Radcure, which were partially offset by lower selling

Edgar Filing: CYTEC INDUSTRIES INC/DE/ - Form 10-Q

prices in powder coating resins due to competitive challenges. Changes in exchange rates increased sales by 10%.

Earnings from operations were \$64.6, or 5% of sales in 2008, down from \$79.7, or 6% of sales in 2007. Earnings were positively impacted \$21.0 by increases in selling prices, \$8.1 by changes in exchange rates and \$1.6 due to higher fixed cost absorption into inventory due to the lower demand. Earnings were negatively impacted \$16.6 due to higher raw material costs, \$11.2 due to lower selling volumes, \$8.5 due to higher manufacturing costs primarily related to inflation and freight costs, and \$5.4 due to higher operating costs also due to inflation. Earnings were also negatively impacted in 2008 by \$4.2 in incremental accelerated depreciation on assets at our Pampa, Texas site that we have decided to exit and consolidate production.

Cytec Performance Chemicals

	2008	2007	Total % Change	% Change Due to		
				Price	Volume/Mix	Currency
North America	\$201.8	\$198.4	2%	6%	-4%	-
Latin America	96.5	93.4	3%	4%	-2%	1%
Asia/Pacific	107.9	97.2	11%	9%	-1%	3%
Europe/Middle East/Africa	176.8	155.6	14%	4%	-	10%
Total	\$583.0	\$544.6	7%	5%	-2%	4%

Overall sales were up 7%. Selling volumes were down 2% primarily due to the completion of a resale agreement related to the sale of the water treating chemicals product line in the prior year and lower volumes across all businesses except mining chemicals which had a 12% increase. Selling volumes were down in most regions except for mining chemicals, which had volume increases across all regions due to strong demand, new products and new business. Overall selling prices increased 5% with increases across all product lines and regions to offset raw materials price increases. Changes in exchange rates increased sales by 4%.

Earnings from operations were \$62.9, or 11% of sales in 2008, up from \$54.9 or 10% of sales in 2007. Earnings were positively impacted \$27.9 by higher selling prices, \$3.6 by favorable product mix, \$3.2 due to changes in exchange rates, and \$1.0 due to higher fixed cost absorption into inventory due to a combination of lower demand and the timing of production campaigns. Earnings were negatively impacted \$24.6 due to higher raw material costs, \$1.4 due to higher manufacturing costs related to inflation and \$1.5 higher operating costs due to increased commercial efforts in mining chemicals and inflation.

Cytec Engineered Materials

	2008	2007	Total % Change	% Change Due to		
				Price	Volume/Mix	Currency
North America	\$361.2	\$311.8	16%	3%	13%	-
Latin America(1)	1.1	0.9	-	-	-	-
Asia/Pacific	44.5	36.9	21%	1%	20%	-

Edgar Filing: CYTEC INDUSTRIES INC/DE/ - Form 10-Q

Europe/Middle East/Africa	177.7	142.7	25%	2%	22%	1%
Total	\$584.5	\$492.3	19%	3%	16%	-

(1) Due to the level of sales in this geographic region, percentage comparisons are not meaningful.

Overall sales increased 19%. Selling volumes increased 16% from higher volumes to the business/regional jet and rotorcraft commercial transport market sectors. Net selling prices increased 3% due to price increases across most market sectors and regions.

-26-

Earnings from operations were \$124.2, or 21% of sales in 2008, up from \$96.2, or 20% of sales in 2007. The \$28.0 increase in earnings included \$46.9 due to higher selling volumes, \$12.4 due to higher selling prices, and \$3.5 due to increased fixed cost absorption as a result of higher production levels. Earnings were negatively impacted by \$6.2 due to higher raw material costs, \$18.8 due to higher manufacturing costs primarily related to the higher production volumes, and \$8.1 due to higher operating costs of which approximately \$5.3 related to increased investments in research and development and technical service costs. Earnings were negatively impacted \$1.7 due to changes in exchange rates.

Building Block Chemicals

	2008	2007	Total % Change	% Change Due to		
				Price	Volume/Mix	Currency
North America	\$295.7	\$178.3	66%	60%	6%	-
Latin America(1)	5.0	2.4	-	-	-	-
Asia/Pacific	12.9	23.4	-45%	8%	-53%	-
Europe/Middle East/Africa	104.0	124.6	-17%	19%	-36%	-
Total	\$417.6	\$328.7	27%	41%	-14%	-

(1) Due to the level of sales in this geographic region, percentage comparisons are not meaningful.

Overall sales were up 27%. Selling volumes were down 14% primarily due to lower volumes of acrylonitrile. We are seeing demand destruction in acrylic fibers primarily in Asia and Europe due to high costs for acrylonitrile. Overall selling prices increased 41% to offset higher raw material price increases across all products.

Earnings from operations were \$11.1, or 3% of sales in 2008, down from \$16.6, or 5% of sales in 2007. Earnings were positively impacted by a \$133.6 increase in selling prices and \$5.3 of higher fixed cost absorption into inventory due to higher production than demand primarily in acrylonitrile product line. Earnings in 2008 were negatively impacted \$115.5 due to higher raw material costs, \$17.8 related to lower selling volumes, and \$11.7 of higher manufacturing costs of which \$3.0 was related to hurricane Gustav and \$8.0 was related to lower acid regeneration operations and a maintenance turn-around.

LIQUIDITY AND FINANCIAL CONDITION

Edgar Filing: CYTEC INDUSTRIES INC/DE/ - Form 10-Q

At September 30, 2008 our cash balance was \$90.2 compared with \$76.8 at December 31, 2007.

Cash flows provided by operating activities were \$170.5 in 2008 compared with \$194.5 in 2007. Trade accounts receivable increased \$48.7 reflecting the increase in sales while our days sales outstanding remained flat. Inventory increased \$97.1 primarily due to higher raw material costs and higher days of inventory on hand. The inventory days was influenced primarily by a slowdown in demand in our Specialty Chemical and Building Block Chemical segments at the latter part of the third quarter for which our operations were not able to adjust production levels to the lower demand by the end of the reporting period. Other liabilities decreased \$22.2 which includes pension and other postretirement benefit contributions of \$29.2 partially offset by current year accruals of \$16.5 and environmental remediation spending of \$3.9. Accounts payable increased \$39.3 primarily reflecting the increased raw material costs.

Cash flows used in investing activities were \$121.0 compared with \$35.5 for 2007. In 2007, we received \$30.2 related to the divestiture of our water treatment and acrylamide product lines. Capital spending for the first nine months of 2008 was \$116.3 mostly related to work on a new carbon fiber line, a prepreg plant in China, and capacity expansions for waterborne and Radcure resins. Total capital spending for 2008 is forecasted to be in a range of \$180 to \$200.

Net cash flows used by financing activities were \$34.7 in 2008 compared with \$116.3 in 2007. During the first nine months of 2008, we had net debt borrowings of \$15.5, treasury stock repurchases of 908,400 shares for \$46.4, and cash dividends of \$17.9, which was partially offset by proceeds received on the exercise of stock options of \$10.8.

Approximately \$45.0 remained authorized under our stock buyback program as of September 30, 2008. We anticipate repurchases will be made from time-to-time on the open market or in private transactions and will be utilized for share-based compensation plans and other corporate purposes.

At September 30, 2008, we have \$280.0 of borrowing capacity available under our \$400.0 revolving credit facility.

On July 17, 2008 the Board of Directors declared a \$0.125 per common share cash dividend, which was paid on August 25, 2008 to shareholders of record as of August 11, 2008. Cash dividends paid in the third quarter of 2008 and 2007 were \$6.0 and \$4.8, respectively, and for the nine months ended September 30, 2008 and 2007 were \$17.9 and \$14.4, respectively. On October 16, 2008 the Board of Directors declared a \$0.125 per common share cash dividend, which is payable on November 25, 2008 to shareholders of record as of November 10, 2008.

-27-

We believe that we have the ability to fund our operating cash requirements, planned capital expenditures and dividends as well as the ability to meet our debt service requirements for the foreseeable future from existing cash and internal cash generation and/or available borrowing capacity.

We have not guaranteed any indebtedness of our unconsolidated associated company.

Excluding the impact of increasing raw materials prices, inflation at this time is not considered significant although higher costs for energy and commodities could impact our future operating expenses and capital spending. The impact of increasing raw material costs are discussed under "Customers and Suppliers" in

Edgar Filing: CYTEC INDUSTRIES INC/DE/ - Form 10-Q

"Business" in Item 1 in our 2007 Annual Report on Form 10-K.

The portion of our pension and postretirement plan assets invested in equity securities have experienced negative returns in line with the decline in the market. If returns from equity securities remain at the current level, contributions to our pension and other postretirement plans in 2009 could double from the expected full year 2008 contributions of \$49.2 million, or could increase further if returns from equity securities continue to deteriorate from current valuation levels.

There were no material changes in contractual obligations from December 31, 2007 to September 30, 2008. Reference is also made to Note 11 in the Notes to Consolidated Financial Statements included herein which describes certain gross liabilities totaling \$39.7 for unrecognized tax benefits that will be resolved at some point over the next several years.

OTHER

2008 OUTLOOK

In our October 9 and October 16, 2008 press releases, which were also furnished as exhibits to current reports on Form 8-K, we presented our best estimate of the full year 2008 earnings at the time based on various assumptions set forth in the press release. There can be no assurance that sales or earnings will develop in the manner projected. Actual results may differ materially.

The press releases noted above also discussed that our chemical operations are being impacted by weakening market conditions in Europe, North America and Asia. In response to these conditions, we are accelerating our review of company-wide operations to ensure our organization and asset base is consistent with our latest view of the global economy.

In addition, we are expecting to see a slowdown in orders as a result of a strike at one of our major customers in the Engineered Materials segment, although we believe the long-term outlook for the markets served by this segment remain strong.

See "Comments on Forward Looking Statements."

SIGNIFICANT ACCOUNTING ESTIMATES / CRITICAL ACCOUNTING POLICIES

See "Critical Accounting Policies" under Item 7A of our 2007 Annual Report on Form 10-K, filed with the Securities and Exchange Commission on February 28, 2008 and incorporated by reference herein. There were no changes to our critical accounting policies except as follows.

Fair Value Measurements

During the first quarter of 2008, we adopted SFAS No. 157, "Fair Value Measurements", ("SFAS 157") for financial assets and liabilities, as well as for any other assets and liabilities that are carried at fair value on a recurring basis in financial statements. SFAS 157 establishes a single authoritative framework for measuring fair value, and requires additional disclosures about fair value measurements. The fair value hierarchy in SFAS 157 prioritizes the inputs, which refer broadly to assumptions market participants would use in pricing an asset or liability, into three levels. It gives the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Level 2 inputs are inputs other than quoted prices within Level 1 that are observable for the asset or liability, either directly or indirectly, such as quoted prices for similar

Edgar Filing: CYTEC INDUSTRIES INC/DE/ - Form 10-Q

assets or liabilities in active markets, interest rates, exchange rates, and yield curves observable at commonly quoted intervals. Level 3 inputs are unobservable inputs for the asset or liability.

All of our derivatives are valued based on level 2 inputs. Our gas swaps and currency forwards are valued based on readily available published indices for commodity prices and currency exchange rates. Our cross currency swaps are valued using an income approach based on industry-standard techniques. This model includes a discounted cash flow analysis that nets the discounted future cash receipts and the discounted expected cash payments resulting from the swap. The analysis is based on the contractual terms of the swaps including the period to maturity and observable market-based inputs that include time value, interest rate curves, exchange rates, implied volatilities, as well as other relevant economic measures. We incorporate credit valuation adjustments to appropriately reflect both our own nonperformance risk and the counterparty's nonperformance risk in the fair value measurements.

-28-

At September 30, 2008, the unfavorable fair values of the five and ten year swaps were \$36.0 and \$25.0, respectively. The following table summarizes the approximate impact that a change in certain critical inputs would have on the fair values of our cross currency swaps in total. The approximate impact of the change in each critical input assumes all other inputs and factors remain constant. See Note 15 of the Consolidated Financial Statements for additional details on SFAS 157 disclosures.

Critical Factors	Change	Approximate Impact On Five and Ten Year Swaps Favorable/ (Unfavorable) Fair Value Combined
Euro interest rate curve	+10%	\$11.2
Euro interest rate curve	-10%	(11.5)
USD interest rate curve	+10%	(8.4)
USD interest rate curve	-10%	8.6
Euro/USD exchange rate	+10%	(64.4)
Euro/USD exchange rate	-10%	64.3

COMMENTS ON FORWARD-LOOKING STATEMENTS

A number of the statements made by us in this report, in our Annual Report on Form 10-K, or in other documents, including but not limited to the Chairman, President and Chief Executive Officer's letter to Stockholders, our press releases and other periodic reports to the Securities and Exchange Commission, may be regarded as "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.

Forward-looking statements include, among others, statements concerning: our or any of our segments outlooks for the future, anticipated results of acquisitions and divestitures, selling price and raw material cost trends, the effects of changes in currency rates and forces within the industry, anticipated costs, the completion dates of and anticipated expenditures for capital projects, expected

Edgar Filing: CYTEC INDUSTRIES INC/DE/ - Form 10-Q

sales growth, operational excellence strategies and their results, expected annual underlying tax rates, our long-term goals, future legal settlements and other statements of expectations, beliefs, future plans and strategies, anticipated events or trends and similar expressions concerning matters that are not historical facts. Such statements are based upon our current beliefs and expectations and are subject to significant risks and uncertainties. Actual results may vary materially from those set forth in the forward-looking statements.

The following factors, among others, could affect our anticipated results: our ability to successfully complete planned or ongoing restructuring and capital expansion projects, including realization of the anticipated results from such projects; our ability to maintain or improve current ratings on our debt; worsening conditions in the financial markets that may affect us, our customers, and suppliers; timely access to capital markets; changes in global and regional economies; the financial well-being of end consumers of our products; changes in demand for our products or in the quality, costs and availability of our raw materials and energy; customer inventory reductions; the actions of competitors; currency and interest rate fluctuations; technological change; our ability to renegotiate expiring long-term contracts; our ability to raise our selling prices when our product costs increase; changes in employee relations, possible strikes or work stoppages at our facilities or at the facilities of our customers or suppliers; changes in laws and regulations or their interpretation, including those related to taxation and those particular to the purchase, sale and manufacture of chemicals or operation of chemical plants; governmental funding for those military programs that utilize our products; litigation, including its inherent uncertainty and changes in the number or severity of various types of claims brought against us and changes in the laws applicable to these claims; quality problems with our products; difficulties in plant operations and materials transportation, including those caused by hurricanes or other natural forces; environmental matters; returns on employee benefit plan assets and changes in the discount rates used to estimate employee benefit liabilities; changes in the medical cost trend rate; changes in accounting principles or new accounting standards; political instability or adverse treatment of foreign operations in any of the significant countries in which we operate; war, terrorism or sabotage; epidemics; and other unforeseen circumstances.

-29-

Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK (Currencies in millions)

For a discussion of market risks at year-end, refer to Item 7A of our Annual Report on Form 10-K for the year ended December 31, 2007, filed with the Securities and Exchange Commission on February 28, 2008 and incorporated by reference herein. Other 2008 financial instrument transactions include:

Commodity Price Risk: At September 30, 2008, we held natural gas swaps, with an unfavorable fair value of \$10.5 included in accrued expenses, which will be reclassified into Manufacturing Cost of Sales through September 2009 as the hedged natural gas purchases affect earnings.

Assuming all other factors are held constant, a hypothetical increase/decrease of 10% in the price of natural gas would cause an increase/decrease of approximately \$2.9 in the value of the swaps.

Interest Rate Risk: At September 30, 2008, our outstanding borrowings consisted of \$39.8 of short-term borrowings and \$825.0 of long-term debt, including the current portion. The long-term debt had a carrying and face value of \$825.0 and \$824.5, respectively, and a fair value of approximately \$786.5.

Edgar Filing: CYTEC INDUSTRIES INC/DE/ - Form 10-Q

Assuming other factors are held constant, a hypothetical increase/decrease of 1% in the weighted-average prevailing interest rates on our variable rate debt outstanding as of September 30, 2008, interest expense would increase/decrease by approximately \$0.4 for the next fiscal quarter.

Currency Risk: We periodically enter into currency forward contracts primarily to hedge currency fluctuations of transactions denominated in currencies other than the functional currency of the respective entity. At September 30, 2008, the principal transactions hedged involved accounts receivable, accounts payable and intercompany loans. When hedging currency exposures, our practice is to hedge such exposures with forward contracts denominated in the same currency and with similar critical terms as the underlying exposure, and therefore, the instruments are effective at generating offsetting changes in the fair value, cash flows or future earnings of the hedged item or transaction.

At September 30, 2008, the net contractual amounts of forward contracts outstanding translated into U. S. dollar equivalent amounts totaled \$80.8. The net unfavorable fair value of currency contracts, based on forward exchange rates at September 30, 2008, was approximately \$2.3. Assuming that period-end exchange rates between the underlying currencies of all outstanding contracts and the various hedged currencies were to adversely change by a hypothetical 10%, the fair value of all outstanding contracts at September 30, 2008 would decrease by approximately \$12.4. However, since these contracts hedge specific transactions, any change in the fair value of the contracts would be offset by changes in the underlying value of the item or transaction being hedged.

In September, 2005, we entered into (euro)207.9 of five year cross currency swaps and (euro)207.9 of ten year cross currency swaps to effectively convert the five-year notes and ten-year notes into Euro-denominated liabilities. The swaps included an initial exchange of \$500.0 on October 4, 2005 and will require final principal exchanges of \$250.0 and (euro)207.9 on each settlement date of the five-year and ten-year notes (October 1, 2010 and October 1, 2015), respectively. At the initial principal exchange, we paid U.S. dollars to counterparties and received Euros. Upon final exchange, we will provide Euros to counterparties and receive U.S. dollars. The swaps also call for a semi-annual exchange of fixed Euro interest payments for fixed U.S. dollar interest receipts. With respect to the five year swaps, we will receive 5.5% per annum and will pay 3.78% per annum on each April 1 and October 1, through the maturity date of the five year swaps. With respect to the ten year swaps, we will receive 6.0% per annum and will pay 4.52% per annum on each April 1 and October 1, through the maturity date of the ten year swaps. The cross currency swaps have been designated as cash flow hedges of the changes in value of the future Euro interest and principal receipts that results from changes in the U.S. dollar to Euro exchange rates on certain Euro denominated intercompany receivables we have with one of our subsidiaries. At September 30, 2008, the unfavorable fair values of the five and ten year swaps were \$36.0 and \$25.0, respectively. Assuming other factors are held constant, a hypothetical increase of 10% in the euro exchange rate would have an adverse effect of approximately \$64.4 on the combined settlement value of the cross-currency swaps.

A portion of an intercompany Euro denominated loans payable naturally hedges our net investment in our Belgium-based subsidiary, Cyttec Surface Specialties SA/NV. From time to time we also enter into designated forward Euro contracts to adjust the amount of the net investment hedge. At September 30, 2008, we had no designated forward Euro contracts.

-30-

Item 4. CONTROLS AND PROCEDURES

We carried out an evaluation, under the supervision and with the participation

Edgar Filing: CYTEC INDUSTRIES INC/DE/ - Form 10-Q

of the management, including the Chief Executive Officer and Chief Financial Officer, of the effectiveness of the Company's disclosure controls and procedures as required by Exchange Act Rule 13a-15(b) as of the period ended September 30, 2008. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that the Company's disclosure controls and procedures are effective.

We continue the process of implementing our Cytec Specialty Chemicals global enterprise-wide planning systems for the acquired business of Surface Specialties. The world-wide implementation is expected to be completed in 2010 and includes changes that involve internal control over financial reporting. Although we expect this implementation to proceed without any material adverse effects, the possibility exists that the migration to our global enterprise-wide planning systems could adversely affect our internal control, our disclosure control and procedures or our results of operations in future periods. We are reviewing each system and site as they are being implemented and the controls affected by the implementation. Appropriate changes have been or will be made to any affected internal control during the implementation. We will test all significant modified controls resulting from the implementation to ensure they are functioning effectively.

As of August 1, 2008, we began utilizing the aforementioned global systems for the acquired Surface Specialties subsidiary in Brazil. We have reviewed the results of the systems implementation and have concluded that it did not have a negative impact on our internal control over financial reporting.

With the exception of the matters discussed above, there were no other changes in internal control over financial reporting that occurred during the quarter ended September 30, 2008 that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

-31-

PART II - OTHER INFORMATION

Item 1. LEGAL PROCEEDINGS

Information regarding legal proceedings is included in Note 9 to the Consolidated Financial Statements herein and in Note 13 to the Consolidated Financial Statements contained in our 2007 Annual Report on Form 10-K.

Item 1A. RISK FACTORS

In addition to the other information set forth in this report on Form 10-Q, you should carefully consider the factors discussed in Part I, Item 1A. Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2007 and the factors noted below, which could materially affect our business, financial condition or future results.

The current global economic weakness coupled with a lack of credit availability from the credit markets could adversely impact our customers and, their ability to pay their accounts receivable to us. The current market conditions could also adversely impact our suppliers and their ability to supply our materials requirements.

We regularly review our customers and suppliers financial viability to determine where we are at risk if they were unable to secure the financing necessary to continue as a going concern. See "Item 1. Business - Customers and Suppliers in our annual report on Form 10-K for the year ended December 31, 2007.

Edgar Filing: CYTEC INDUSTRIES INC/DE/ - Form 10-Q

Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS (Currencies in millions, except per share amounts)

During the nine months ended September 30, 2008, we repurchased common stock for \$46.4 under our stock buyback program. Approximately \$45 remained authorized under the buyback program as of September 30, 2008. Pursuant to this program, shares can be repurchased in open market transactions or privately negotiated transactions at our discretion.

Period	Total Number of Shares Purchased	Average Price Per Share	Total Number of Shares Purchased as Part of Publicly Announced Program	Approximate Dollar Value of Shares That May Yet Be Purchased Under the Program
March 1, 2008 - March 31, 2008	100,900	\$53.62	100,900	\$86.0
May 1, 2008 - May 31, 2008	142,500	\$61.84	142,500	\$77.0
June 1, 2008 - June 30, 2008	90,000	\$58.46	90,000	\$72.0
August 1, 2008 - August 31, 2008	155,000	\$51.36	155,000	\$64.0
September 1, 2008 - September 30, 2008	420,000	\$45.12	420,000	\$45.0
Total	908,400		908,400	

-32-

Item 6. EXHIBITS

(a). Exhibits

See Exhibit Index on page 35 for exhibits filed with this Quarterly Report on Form 10-Q.

-33-

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

CYTEC INDUSTRIES INC.

Edgar Filing: CYTEC INDUSTRIES INC/DE/ - Form 10-Q

By: /s/ David M. Drillock

David M. Drillock
Vice President and
Chief Financial Officer

October 30, 2008

-34-

Exhibit Index

-
- 12 Computation of Ratio of Earnings to Fixed Charges for the three and nine months ended September 30, 2008 and 2007
 - 31.1 Certification of David Lilley, Chairman of the Board and Chief Executive Officer, Pursuant to Rule 13a-14(a) of the Securities Exchange Act
 - 31.2 Certification of David Drillock, Chief Financial Officer, Pursuant to Rule 13a-14(a) of the Securities Exchange Act
 - 32.1 Certification of David Lilley, Chairman of the Board and Chief Executive Officer Pursuant To 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of The Sarbanes-Oxley Act of 2002
 - 32.2 Certification of David Drillock, Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of The Sarbanes-Oxley Act of 2002

-35-